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Introduction
Executive Summary
This report focuses on patent landscape analysis of technologies related to prophylactic vaccines
targeting pandemic strains of influenza. These technologies include methods of formulating
vaccine, methods of producing of viruses or viral subunits, the composition of complete
vaccines, and other technologies that have the potential to aid in a global response to this
pathogen. The purpose of this patent landscape study was to search, identify, and categorize
patent documents that are relevant to the development of vaccines that can efficiently promote
the development of protective immunity against pandemic influenza virus strains.
The search strategy used keywords which the team felt would be general enough to capture (or
“recall”) the majority of patent documents which were directed toward vaccines against
influenza A virus. After extensive searching of patent literature databases, approximately 33,500
publications were identified and collapsed to about 3,800 INPADOC families. Relevant
documents, almost half of the total, were then identified and sorted into the major categories of
vaccine compositions (about 570 families), technologies which support the development of
vaccines (about 750 families), and general platform technologies that could be useful but are not
specific to the problems presented by pandemic influenza strains (about 560 families). The first
two categories, vaccines and supporting technologies, were further divided into particular
subcategories to allow an interested reader to rapidly select documents relevant to the particular
technology in which he or she is focused. This sorting process increased the precision of the
result set.
The two major categories (vaccines and supporting technologies) were subjected to a range of
analytics in order to extract as much information as possible from the dataset. First, patent
landscape maps were generated to assess the accuracy of the sorting procedure and to reveal the
relationships between the various technologies that are involved in creating an effective vaccine.
Then, filings trends are analyzed for the datasets. The country of origin for the technologies was
determined, and the range of distribution to other jurisdictions was assessed. Filings were also
analyzed by year, by assignee, and by inventor. Finally, the various patent classification systems
were mapped to find which particular classes tend to hold influenza vaccine-related technologies.
Besides the keywords developed during the searches and the landscape map generation, the
classifications represent an alternate way for further researchers to identify emerging influenza
technologies.
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ThemeScape map of terms from influenza vaccine patent documents. This category contained
approximately 570 INPADOC patent families. See Figure 10.

The analysis included creation of a map of keywords, as shown above, describing the
relationship of the various technologies involved in the development of prophylactic influenza A
vaccines. The map has regions corresponding to live attenuated virus vaccines, subunit vaccines
composed of split viruses or isolated viral polypeptides, and plasmids used in DNA vaccines.
Important technologies listed on the map include the use of reverse genetics to create reassortant
viruses, the growth of viruses in modified cell lines as opposed to the traditional methods using
eggs, the production of recombinant viral antigens in various host cells, and the use of
genetically-modified plants to produce virus-like particles.
Another major finding was that the number of patent documents related to influenza being
published has been steadily increasing in the last decade, as shown in the figure below. Until the
mid-1990s, there were only a few influenza patent documents being published each year. The
number of publications increased noticeably when TRIPS took effect, resulting in publication of
patent applications. However, since 2006 the number of vaccine publications has exploded. In
each of 2011 and 2012, about 100 references disclosing influenza vaccine technologies were
published. Thus, interest in developing new and more efficacious influenza vaccines has been
5
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Publication trends for influenza vaccine documents. Publications increased in the 1990s when
patent applications began to be published, and then the numbers soared after outbreaks of H5N1
and H1N1. Similar results were observed with documents related to supporting technologies.
See Figure 16.

growing in recent years. This interest is probably being driven by recent influenza outbreaks,
such as the H5N1 (bird flu) epidemic that began in the late 1990s and the 2009 H1N1 (swine flu)
pandemic.
The origins of the vaccine-related inventions were also analyzed. The team determined the
country in which the priority application was filed, which was taken as an indication of the
country where the invention was made or where the inventors intended to practice the invention.
By far, most of the relevant families originated with patent applications filed in the United
States. Other prominent priority countries were the China and United Kingdom, followed by
Japan, Russia, and South Korea. France was a significant priority country only for supporting
technologies, not for vaccines. Top assignees for these families were mostly large
pharmaceutical companies, with the majority of patent families coming from Novartis, followed
by GlaxoSmithKline, Pfizer, U.S. Merck (Merck, Sharpe, & Dohme), Sanofi, and AstraZeneca.
Governmental and nonprofit institutes in China, Japan, Russia, South Korea and the United
States also are contributing heavily to influenza vaccine research.
Lastly, the jurisdictions were inventors have sought protection for their vaccine technologies
were determined, and the number of patent families filing in a given country is plotted on the
6

Jurisdictions for filing applications and issuing patents related to influenza vaccines. Filings in
multi-jurisdictional agencies, such as ARIPO, the Gulf Cooperation Council, WIPO and the
European Patent Office, are not shown. The number of patent families is out of 570 total
families. See Figure 15 for a more detailed description.

world map shown below. The United States, Canada, Australia, Japan, South Korea and China
have the highest level of filings, followed by Germany, Brazil, India, Mexico and New Zealand.
However, although there are a significant number of filings in Brazil, the remainder of Central
and South America has only sparse filings. Of concern, with the exception of South Africa, few
other African nations have a significant number of filings.
In summary, the goal of this report is to provide a knowledge resource for making informed
policy decisions and for creating strategic plans concerning the assembly of efficacious vaccines
against a rapidly-spreading, highly virulent influenza strain. The team has defined the current
state of the art of technologies involved in the manufacture of influenza vaccines, and the
important assignees, inventors, and countries have been identified. This document should reveal
both the strengths and weaknesses of the current level of preparedness for responding to an
emerging pandemic influenza strain. The effects of H5N1 and H1N1 epidemics have been felt
across the globe in the last decade, and future epidemics are very probable in the near future, so
preparations are necessary to meet this global health threat.
7
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Disclaimer
This educational report is neither inclusive nor comprehensive. Rather, it is an informational
resource intended to facilitate a better understanding of the international patent literature
landscape regarding vaccines against influenza A viruses.
This report is not a list of all potentially relevant patents. Importantly, it is not a Freedom to
Operate (FTO) opinion, but instead constitutes an educational analysis of potentially relevant
material. While the search platforms utilized in this project were extensive, none were
comprehensive, and some countries and jurisdictions were underrepresented in the databases,
either in the time frame covered, the availability of translated documents, and the completeness
of the records. Further, it is likely that the International Technology Transfer Institute (ITTI)
team did not obtain the entire spectrum of relevant patents utilizing the various search strategies
and methods articulated herein. Therefore, the ITTI team does not guarantee that all relevant
patents were discovered during the creation of this report.
As the ITTI team members are not experts in the field of influenza A virus related vaccines, it is
likely that the categorization of the patents found and coded are incomplete. Further, many
patent documents contain material relevant to multiple categories; the documents were placed in
the category that the team, in its judgment, felt best represented the overall focus of the
document. The ITTI team cannot guarantee that the patents discovered were evaluated at the
level of expert scientific sophistication.
The limited time frame, competing academic demands, and the general press of business dictated
the number of patents evaluated. As such, additional patents may have been available that were
not considered due to time constraints.
Many names are capitalized and may or may not be trademarked and/or otherwise protected
intellectual property. The team apologizes for any errors or mistaken omissions.
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Abbreviations and Definitions
Below is a list of abbreviations and definitions for terms and keywords used throughout the ITTI
Fall 2012 report and the reported results.
Adjuvants – defined herein as a substance sometimes included in a vaccine formulation to
enhance or modify the immune-stimulating properties of a vaccine.1
Antibody – defined herein as an infection-fighting protein molecule in blood or secretory fluids
that tags, neutralizes, and helps destroy pathogenic microorganisms (e.g., bacteria, viruses) or
toxins. Antibodies, known generally as immunoglobulins, are made and secreted by Blymphocytes in response to stimulation by antigens. Each specific antibody binds only to the
specific antigen that stimulated its production.2
Antibody-mediated immunity – defined herein as the immunity that results from the activity of
antibodies in blood and lymphoid tissue (also called humoral immunity).3
Antigens - (immunogens; substances capable of provoking an immune response) – defined
herein as foreign substances in the body that are capable of causing disease. The presence of
antigens in the body triggers an immune response, usually the production of antibodies.
Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as
bacteria and tissue cells; however only the portion of the protein of polysaccharide molecule
known as the antigenic determinant combines with antibody or a specific receptor on a
lymphocyte.4
Anti-idiotype - herein defined as a manufactured antibody (Ab2) that can recognize the idiotype
of another antibody (Ab1). Theoretically, the anti-idiotype antibody mimics the structure of the
antigen recognized by Ab1. When Ab2 is injected into the host, the host develops
immunological memory comprising antibodies (Ab3) which have similar specificities as Ab1. 5
Attenuated - weakened or treated in such a way as to decrease the ability of a microorganism
(such as parasite or virus) to cause infection or disease.6
Attenuated vaccine - a vaccine in which live bacteria or viruses are weakened through chemical
or physical processes in order to produce an immune response without causing the severe effects
1

American Heritage Dictionary definition: http://education.yahoo.com/reference/dictionary/entry/adjuvant.
http://medical-dictionary.thefreedictionary.com/antibody.
3
http://medical-dictionary.thefreedictionary.com/humoral+immunity.
4
http://medical-dictionary.thefreedictionary.com/antigen.
5
http://en.wikipedia.org/wiki/Anti-idiotypic_vaccine.
6
http://medical-dictionary.thefreedictionary.com/attenuated+virus.
2
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of the disease. Attenuated vaccines currently licensed in the United States include measles,
mumps, rubella, polio, typhoid, yellow fever, and chickenpox/shingles. This is also known as a
live vaccine.
Attenuation -- defined herein as established by introduction of a heritable genetic alteration or
gene mutation, or by radiation exposure (preferred), chemical exposure or environmental
exposure.
B cells – defined herein as small white blood cells that help the body defend itself against
infection. These cells are produced in bone marrow and develop into plasma cells that produce
antibodies. These cells are also known as B-lymphocytes.7
BLAST – defined herein as the acronym for Basic Local Alignment Search Tool. This
program compares nucleotide or protein sequences to sequence databases and calculates the
statistical significance of matches.
Booster – defined herein as a second or later vaccine dose given after the primary dose(s) to
increase the immune response to the original vaccine antigen(s). The vaccine given as the
booster dose may or may not be the same as the primary vaccine.8
Delivery Systems – defined herein as a method or system by which a vaccine is delivered to the
host body.9
DNA (deoxyribonucleic acid) - defined herein as the double-stranded, helical molecular chain
found within the nucleus of each cell. DNA carries the genetic information that encodes proteins
and enables cells to reproduce and perform their functions.10
DNA vaccine (nucleic acid vaccine) - defined herein as direct injection of a gene(s) coding for a
specific antigenic protein(s), resulting in direct production of such antigen(s) within the vaccine
recipient in order to trigger an appropriate immune response.11
DWPI – defined herein as Derwent World Patent Index, which is the world’s most
comprehensive database of patent documents. DWPI includes over 20 million patent document
families, which covers over 42.5 million patent documents. The DWPI database includes
coverage from over 44 worldwide patent authorities.12
7
8

http://en.wikipedia.org/wiki/B_cell.
http://en.wikipedia.org/wiki/Booster_dose.

Crystal Chan, et. al., Advancing Adjuvants and Vaccine Delivery Systems for Better Vaccination Strategies, BioPharm Int’l Supplements, Jan. 2,
2010.
9

10

http://education.yahoo.com/reference/dictionary/entry/DNA.
http://www.who.int/biologicals/areas/vaccines/dna/en/index.html. See also http://www.dnavaccine.com/.
12
http://thomsonreuters.com/products_services/legal/legal_products/a-z/derwent_world_patents_index/.
11
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Efficacy - defined herein in vaccine research, the ability of a vaccine to produce a desired
clinical effect, such as protection against a specific infection or disease, at the optimal dosage
and schedule in a given population. A vaccine may be tested for efficacy in Phase 3 clinical
trials if it appears to be safe in Phase 1 trials and has shown efficacy at certain dosages in Phase 2
trials.13
Endemic - defined herein as the continual, sometimes low-level presence of disease in a
community.14
Epitope - defined herein as a specific site on an antigen that stimulates specific immune
responses, such as the production of antibodies or activation of immune cells.15
Expression system - defined herein as in genetic engineering, the cells into which a gene has
been inserted into a host cell in order to manufacture desired proteins.16
Functional antibody - defined herein as an antibody that binds to an antigen and has an effect
that can be demonstrated in laboratory tests.17
Gene – defined herein as a unit of genetic material (DNA); a segment of DNA encoding a
protein molecule; a segment of DNA that contains the information for a specific function.18
Hemagglutinin (HA) – a major membrane protein of influenza viruses and thus a frequent target
for immunization strategies to generate protective antibodies. HA recognizes sialic acid residues
on the surface of host cells and it functions to attach viral particles to target cells, leading to
infection of those target cells.19 This term is also spelled haemagglutinin.
Host - defined herein as a plant or animal harboring another organism or a pharmaceutical
composition.20
Immune system - defined herein as the complex system (network of specialized cells and
organs) in the host body responsible for fighting and responding to disease (immune response).
Its primary function is to identify foreign substances (antigens of bacteria, viruses, fungi, or
parasites) in the body and develop a defense against them. It involves production of proteins
13

http://en.wikipedia.org/wiki/Vaccine_efficacy.
http://en.wikipedia.org/wiki/Endemic_%28epidemiology%29.
15
http://medical-dictionary.thefreedictionary.com/epitope.
16
http://www.news-medical.net/health/Gene-Expression-System.aspx.
17
http://en.wikipedia.org/wiki/Antibody.
18
http://en.wikipedia.org/wiki/Gene.
19
http://en.wikipedia.org/wiki/Hemagglutinin_%28influenza%29.
20
http://en.wikipedia.org/wiki/Host_%28biology%29.
14
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called antibodies to eliminate these foreign organisms that have invaded the host, and the
generation of cytotoxic activity to eliminate infected cells.21
Immunity - defined herein as a natural or acquired resistance provided by the immune system to
a specific disease. Immunity may be partial or complete, specific or nonspecific, long lasting or
temporary. Immunity is indicated by the presence of antibodies and antigen-reactive cells in the
blood and can usually be determined with a laboratory test.22
Immunization - defined herein as the process by which a person or animal becomes protected
against a disease; the process of inducing immunity by administering an antigen (vaccine) to
allow the immune system to prevent infection or illness when it subsequently encounters the
infectious agent. This term is often used interchangeably with vaccination or inoculation.23
Influenza- herein defined as a virus originating from the family of RNA viruses
Orthomyxoviridae. The family Orthomyxoviridae contains three genera, Influenzavirus A,
Influenzavirus B, and Influenzavirus C.24
INPADOC (International Patent Document Center) – defined herein as a patent database
maintained by the European Patent Office (EPO).25
ITTI – defined herein as International Technology Transfer Institute, an intellectual
property clinic at the University of New Hampshire School of Law.26
Neuraminidase (NA) - a major membrane protein of influenza viruses and thus a frequent target
for immunization strategies to generate protective antibodies. NA is an enzyme which cleaves
sialic acid residues from proteins on influenza virus membranes, thereby preventing aggregation
of viral particles.27
NCBI – defined herein as the acronym for National Center for Biotechnology
Information. NCBI provides access to biomedical and genomic resources, such as BLAST.28

21

http://en.wikipedia.org/wiki/Immune_system.
http://medical-dictionary.thefreedictionary.com/immunity.
23
http://www.who.int/topics/immunization/en/.
24
http://www.niaid.nih.gov/topics/Flu/understandingFlu/Pages/definitionsOverview.aspx.
25
http://www.epo.org/searching/essentials/patent-families/inpadoc.html.
26
http://law.unh.edu/franklin-pierce-ip-center/international-technology-transfer-institute.
27
MJ Sylte and DL Suarez. 2009. Influenza neuraminidase as a vaccine antigen, Curr. Top. Microbiol. Immunol.
333:227-4.
28
http://www.ncbi.nlm.nih.gov/.
22
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Pandemic Influenza - herein defined as a highly pathogenic virus from the family
Orthomyxoviridae. The viruses that fall under this category have the capacity to spread rapidly
from person to person and have to potential to create a global pandemic.29
Passive immunization – defined herein as the introduction of antibodies or antiserum into a host
to treat an infection, wherein such treatment does not result in immunological memory and longlasting immunity in the host.30
Patent document count – defined herein as an expanded patent family which includes all issued
patents and patent applications that fall within that family.
Patent family – defined herein as a group of patent documents having a commonality such as
priority document (INPADOC) or claimed invention (DWPI). The patent documents can be
from any jurisdiction.
PCT – defined herein as the Patent Cooperation Treaty, which is an international treaty
whose goal is to provide a unified procedure for filing patent applications in the contracting
states. A contracting state is a country which has signed onto the treaty. A patent application
filed under the PCT is commonly referred to as an international application, or PCT
application.31
Pharmaceutical Compositions – defined herein as the combination of distinct parts or elements
to form a whole relating to pharmacy, drugs, or medicine. This can include anything from
vitamins, antibodies, antigens, medicaments, and adjuvants.
Seasonal Influenza - herein defined as a virus from the family Orthomyxoviridae that regularly
infects humans between early fall and late winter seasons.32
Vaccine - defined herein as a preparation that stimulates an immune response that can prevent an
infection or create resistance to an infection based upon an antibody response to an antigen.33
Veterinary Vaccines- herein defined as vaccines for pandemic influenza for the specific use in
non-human animals. Target animals include fowl (chicken, ducks, geese, etc.), pigs, horses, and
dogs.34

29

http://www.cdc.gov/flu/pandemic-resources/.
http://en.wikipedia.org/wiki/Passive_immunity.
31
http://www.wipo.int/pct/en/texts/articles/atoc.htm.
32
http://www.flu.gov/about_the_flu/seasonal/index.html#.
33
http://en.wikipedia.org/wiki/Vaccine.
34
http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=1731.
30
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Background of the Technology
Influenza Infections: The Disease
Influenza, more commonly known throughout the world as the flu,35 is a highly infectious
disease caused by the RNA virus family Orthomyxoviridae. The family Orthomyxoviridae
consists of three genera of viruses, influenza A, influenza B, and influenza C. Influenza is
believed to have originated in birds as this family of viruses has resided in birds for millions of
years and generally does them no harm.36 An influenza-like disease was described as early as
412 BC by Hippocrates, and the term influenza first appeared in 1357. The first known influenza
pandemic began in 1580.37
Influenza viruses frequently mutate and can readily jump the species barrier from wild birds to
domesticated fowl, such as chickens, ducks or geese, and finally to pigs.38 Pigs can be infected
by both avian influenza and forms of influenza that can infect humans.39 In a setting such as a
farm where chickens, humans, and pigs live in close proximity, pigs can be infected with avian
and human flu simultaneously and the two types of virus may exchange genes in a process called
genetic drift.40 Such a "reassorted" flu virus can sometimes spread from pigs to people.41 It is
these reassorted viruses that are believed to be the strains that can cause an influenza pandemic.
Nature of an outbreak of a pandemic strain
As previously mentioned, influenza pandemics occur when a new strain of the influenza virus is
transmitted from another animal species to human.42 These novel strains are unaffected by any
immunity people may have to older strains of human influenza and can therefore spread
extremely rapidly and infect very large numbers of people. Within the past 150 years roughly
five influenza pandemics have occurred, the 1918 influenza (H1N1) being the earliest and
deadliest of the pandemics.43 Subsequent pandemics were Asian influenza (H2N2) in 1957 and
Hong Kong influenza (H3N2) in 1968. The 2009 swine influenza (H1N1) pandemic was the
most recent.44 Because the avian influenza (H5N1, or bird flu), first identified in 1997, was not
transmitted directly from humans to humans, this outbreak is only termed an epidemic.45

35

The term “flu” is often also used to describe infections by viruses other than influenza, so the more exact term
“influenza” is used in this report.
36

37

http://www.ncbi.nlm.nih.gov/pubmed/7821758.

http://www.naturalnews.com/026178_flu_influenza_bird.html.

38

http://www.ncbi.nlm.nih.gov/pubmed/7821758.
39
Id.
40
Id.
41
Id.
42
Id.
43

http://www.influenzavirusnet.com/history-of-influenza.html.
http://www.flu.gov/pandemic/history/index.html#.
45
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004522/.
44
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An example of a pandemic strain of influenza would be the strain more commonly known as the
1918 Spanish flu. Given this strain of influenza virus was a novel virus to humans and those
infected had no previous immunity to this type of virus, the pathology of this disease was
particularly severe and an estimated 10%-20% of those infected eventually died.46 About a third
of the world’s population was infected and approximately 3%-6% died.47 Given the
technological advances since the 1920’s, such as increased travel and trade, the globalized
society we now live in is far more conducive to the rise of another influenza pandemic, as seen
with the 1957, 1968 and 2009 outbreaks.48

The Influenza Virus and its Lifecycle

Figure 1. A rendition of the structure of
the influenza virus. Image taken from
the California Department of Health
services. “RNP” denotes
ribonucleoprotein, the genetic material of
the virus.

Influenza viruses A, B and C are very similar in overall structure. The influenza virus is made of
a viral envelope containing two main types of glycoproteins, wrapped around a central core.49
The central core contains the viral RNA genome and other viral proteins that package and protect
the RNA. The influenza genome is not a single piece; instead, the genome contains seven or
eight pieces of segmented negative-sense RNA, each piece of RNA containing either one or
two genes, which code for a protein.50 For example, the influenza A genome contains eight
genes on eight pieces of RNA, encoding for 11 proteins: hemagglutinin (HA); neuraminidase
(NA); nucleoprotein (NP); matrix protein (M1); ion channel protein (M2); nonstructural
protein (NS1); nuclear export protein (NEP, also called NS2); a polymerase complex composed
of PA, PB1, and PB2; and the apoptosis-inducing protein PB1-F2.51
Hemagglutinin (HA) and neuraminidase (NA) are two large glycoproteins found on the outside
of the viral particles. HA is a lectin that mediates the binding of the virus to a target cells and
46

http://www.ncbi.nlm.nih.gov/pubmed/7821758.
Id.
Id.
49
http://www.med.ufl.edu/biochem/bch6415/flu%20lecture%20bfv3.pdf.
50
University of Florida School of Medicine: http://www.med.ufl.edu/biochem/bch6415/flu%20lecture%20bfv3.pdf.
51
Id. see also http://www.virology.ws/2009/05/01/influenza-virus-rna-genome/.
47
48
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entry of the viral genome into the target cell.52 NA is involved in the release of progeny virus
from infected cells, by cleaving sugars that bind the mature viral particles.53 The HA proteins
are commonly used as antigens to which antibodies can be raised.54 The influenza A viruses are
classified into subtypes based on antibody responses to HA and NA. These different types of
HA and NA form the basis of the H and N distinctions, for example, H5N1. There are 17
hemagglutinin and 9 neuraminidase subtypes known, but only H1, H2 and H3, and N1 and N2
are commonly found in humans.55,56

Replication
Viruses can replicate only in living cells. Influenza infection and replication is a multi-step
process. First, the virus has to bind to and enter the cell, then deliver its genome to a site where
it can produce new copies of viral proteins and RNA, assemble these components into new viral
particles, and, last, exit the host cell.57
Influenza viruses bind through hemagglutinin onto sialic acid sugars on the surfaces of epithelial
cells, typically in the nose, throat, and lungs.58 The hemagglutinin is then cleaved by a protease,
the cell imports the virus by endocytosis.59

Figure 2. Adapted from
Neumann et al.,
Nature 459, 931-939 (18
June 2009).

52

Id.
http://www.rcsb.org/pdb/101/motm.do?momID=113.
54
http://www.rcsb.org/pdb/101/motm.do?momID=76.
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Once inside the cell, the acidic conditions of the endosome cause two events to occur: first, part
of the hemagglutinin fuses the viral envelope with the vacuole's membrane, then the M2 ion
channel allows protons to move through the viral envelope and acidify the core of the virus,
which causes the core to dissemble and release the viral RNA and core proteins.60 The viral
RNA (vRNA) molecules, accessory proteins and RNA-dependent RNA polymerase are then
released into the cytoplasm.61
These proteins and vRNA form a complex that is transported into the cell nucleus, where the
RNA polymerase begins transcribing complementary positive-sense vRNA.62 The vRNA can be
exported into the cytoplasm and be translated or the vRNA can remains in the nucleus.63 The
newly synthesized viral proteins can be either secreted through the Golgi apparatus onto the cell
surface or transported back into the nucleus to bind vRNA and form new viral genome particles.
Negative-sense vRNAs that form the genomes of future viruses and other viral proteins are
assembled into a virion.64 Next, molecules of hemagglutinin and neuraminidase cluster into a
bulge in the cell membrane. The vRNA and viral core proteins leave the nucleus and enter this
membrane protrusion.65 The mature virus buds off from the cell in a sphere of host phospholipid
membrane, acquiring hemagglutinin and neuraminidase with this membrane coat. As before, the
viruses adhere to the cell through hemagglutinin; the mature viruses detach once
their neuraminidase has cleaved sialic acid residues from the host cell. After the release of new
influenza viruses, the host cell dies.66
Influenza symptoms
In humans, common symptoms of influenza infection are fever, sore throat, muscle pains, severe
headache, coughing, and fatigue.67 Most people who get influenza will recover in a few days to
less than two weeks, but some people will develop complications (such as pneumonia) as a result
of the infection, some of which can be life-threatening.68
Pneumonia, bronchitis, and sinus and ear infections are three examples of complications from
influenza infections.69 Further, influenza can make chronic health problems worse. For
example, people with asthma may experience asthma attacks while they are infected with
influenza, and people with chronic congestive heart failure may have worsening of this condition
that is triggered by influenza.70
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Transmission
Influenza virus shedding (the time during which a person might be infectious) begins a day
before typical symptoms appear; the virus is then released for between 5 to 7 days, although
some people may shed virus for longer periods.71 People who contract influenza are the most
infective between the second and third days after the initial infection takes place.72 The amount
of virus shed appears to correlate with fever, a higher amount of virus being shed when
temperatures are higher.73
Influenza is transmitted in three main ways: by direct transmission (when an infected person
sneezes mucus directly into the eyes, nose or mouth of another person); the airborne route (when
someone inhales the aerosols produced by an infected person coughing, sneezing or spitting) and
through hand-to-eye, hand-to-nose, or hand-to-mouth transmission, either from contaminated
surfaces or from direct personal contact such as a hand-shake.74 In the airborne route, the
droplets that are small enough for people to inhale are between 0.5 to 5 µm in diameter, and
inhaling just one droplet may be enough to cause an influenza infection.75 Although a single
sneeze can release up to 40,000 droplets, most of these droplets are quite large and will quickly
settle out of the air.76
As the influenza virus can persist outside of the body, it can also be transmitted by surfaces such
as banknotes, doorknobs, light switches and other household items contaminated with the virus.77
The length of time the virus will persist on a surface varies, with the virus surviving for one to
two days on hard, non-porous surfaces such as plastic or metal, for about fifteen minutes from
dry paper tissues, and only five minutes on skin.78 However, if the virus is present in mucus, this
can protect it for longer periods (up to 17 days on banknotes). Avian influenza viruses can
survive indefinitely when frozen.79
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Figure 3. Courtesy of the
Public Health Agency of
Canada.

Antigenic Drift and Antigenic Shift
The composition of the influenza virus can change over time. This is accomplished through two
means: antigenic drift and antigenic shift. Antigenic Drift occurs when small changes in the
virus (i.e. point mutations in the viral genome) happen continually over time.80 These gradual
changes can produce new virus strains that may not be recognized by the body's immune system.
A person infected with a particular influenza strain develops antibody against that particular
virus. When a new virus strain appears and infects the person, her antibodies which recognize
the older strains no longer recognize the “new” virus, and re-infection may occur. This explains
why people can get influenza repeatedly. In most years, one or two of the three virus strains in
the influenza vaccine are updated to keep up with the changes in the circulating influenza
viruses. Thus, people who want to be protected from influenza need to get a “flu shot” every
year.81
The other type of change, antigenic shift, is an abrupt, major change in the influenza A viral
genome, resulting in new hemagglutinin and/or new neuraminidase proteins.82 Antigenic shift is
a recombination event between two viral strains such that a new strain emerges from an animal
population. This new strain is so different from subtypes humans have previously seen that most
people do not have immunity to the new virus.83 Such a shift was seen during the spring of
80
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2009, when a new H1N1 virus with a new combination of genes emerged to infect people and
quickly spread, causing a pandemic. While influenza viruses are changing by antigenic drift all
the time, antigenic shift happens only occasionally. Type A viruses undergo both kinds of
changes; influenza type B viruses change only by the more gradual process of antigenic drift. 84
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Figures 4A and 4B. Illustrations
depicting antigenic drift and
antigenic shift. Courtesy of the
U.S. National Institutes of Health.

Types of Vaccines
Whole virus vaccines - This type of vaccine can be comprised of killed whole viruses or
attenuated viruses.85 Attenuated viruses are live viruses that have been cultivated under
conditions that disable their virulent properties, or which use closely related but less dangerous
organisms to produce a broad immune response.86 Attenuated virus vaccines typically provoke
more durable immunological responses and are the preferred type for healthy adults. 87
Attenuated vaccines have some advantages and disadvantages. For example they have the
capacity of transient growth so they give prolonged protection, and no booster dose is required.
However, the attenuated virus may revert to the virulent form and cause disease.88 Attenuated
85

http://www.niaid.nih.gov/topics/vaccines/understanding/pages/typesvaccines.aspx.
Id.
87
Id.
88
Id.
86

22

influenza viruses were traditionally produced in fertilized chicken eggs, but today commercial
production is more commonly accomplished using mammalian cell cultures (Fig. 5).89
Protein subunit – This type of vaccine is formed by introducing a fragment of microorganism to
the immune system to create an immune response.90 Examples include the subunit vaccine
against Hepatitis B virus that is composed of only the surface proteins of the virus.91
DNA vaccines – These vaccines use modified. This modified DNA is injected into the cells of
the body, where the "inner machinery" of the host cells "reads" the DNA and uses it to
synthesize the pathogen's proteins.92 Because these proteins are recognized as foreign, when
they are processed by the host cells and displayed on their surface, the immune system is alerted,
which then triggers a range of immune responses.93

Figure 5. Production of
recombinant viruses in cell
lines.
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Scope of the Project
The ITTI team began this project after consultation with Dr. Anatole Krattiger, Director of the
Global Challenges Division at the World Intellectual Property Organization (WIPO). After the
discussion, the subject of the project was set to the produce a patent landscape report surveying
the technologies necessary to produce a vaccine targeted against an outbreak of pandemic
influenza. For such a broad subject the ITTI team needed to limit the scope of the project. The
ITTI team set the scope of the project to include the following: all types of complete vaccines,
veterinary vaccines, novel viruses, methods of vaccine production and formulation, methods of
producing viruses or viral subunits, and general platforms related to influenza vaccines.
The ITTI team decided that complete vaccines are relevant to the subject and thus fall within the
scope of the project. Although the ITTI team did not know all of the types of vaccines patents a
landscape analysis would discover, the ITTI team subdivided the vaccine category into
whole/attenuated virus vaccines, subtype vaccines, and DNA vaccines.
In reviewing the patents related to vaccines, the ITTI team recognized the need to address the
issue of when the claims of a patent were directed to vaccines mainly used in animals. Given
that a pandemic often involves transmission of virus from animals to humans, and that there is a
need to vaccinate livestock against influenza, vaccines directed solely to the use in animals were
included as relevant documents and given a separate category.
Another important decision was whether or not to include vaccines and related technologies only
covering seasonal influenza. The issue arose as some seasonal vaccine technologies could be
potentially adapted to be used to treat pandemic strains of influenza. The ITTI team decided to
include technologies that were used for both seasonal and pandemic influenza and for some
seasonal influenza technologies but not vaccines or antigens restricted solely to seasonal
influenza.
One of the most important decisions made was how to deal with adjuvants. The main problem
with adjuvants is that an adjuvant patent often claims use in vaccines for pandemic influenza in a
large Markush group, along with hundreds of other diseases. On the other hand, an adjuvant
could be limited to just pandemic influenza. Faced with these two issues, adjuvants were divided
into two groups, general adjuvants, defined as an adjuvant that listed pandemic influenza in a
large Markush group, would be excluded from the report94 and related adjuvants, defined as
adjuvants used just for pandemic influenza would be considered relevant.95
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Patent Search Methodology
Guess, compute the consequences to see what that guess would imply, and
compare directly with observation to see if it works. If it disagrees with the
experiment, it’s wrong. It’s that simple. It doesn’t matter how beautiful your
guess is, how smart you are, or what your name is. Looking at the universe, the
great power of science, there’s no such thing as authority of nature. If it doesn’t
agree with the experiment, then it’s wrong.
-

Richard Feynman

Iterative Process

Figure 6. Iterative
development model. Taken
from Wikipedia.

The iterative process is defined as the act of repeating a process with the aim of approaching a
desired goal, target, or result. Each repetition of the process is called an iteration, and the results
of one iteration are used as the starting point for the next iteration. In the field of patent
searching, the iterative process is a searching methodology wherein at the end of a search cycle,
the search is evaluated, and its shortcoming assessed. The shortcomings are then addressed in
the next cycle of searches in order to capture the documents. The next search can be either wider
in scope or could be a narrower search depending on the results gained from the previous search.
In this study, keyword searching identified relevant documents, from which were extracted
further keywords as well as classification codes. The classification codes were used to locate
additional documents. Keywords were adjusted and used for another round of searching.
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Precision and Recall96
The number of patent documents worldwide, including patents (issued, re-issued, and reexamined) and applications, is over 60 million97. Selecting relevant documents from such a huge
dataset can be difficult, and this type of document retrieval is governed by the mathematical
theory of Precision and Recall. Precision is the percentage of retrieved documents that are
relevant and is calculated as the number of retrieved relevant documents divided by the total
number of retrieved documents. Recall is the fraction of relevant documents retrieved and is
calculated as the number of retrieved relevant documents divided by the total number of existing
relevant documents. These concepts are illustrated in Figure 798 below.

Figure 7. Increasing precision of a search means some relevant results are excluded.
Thus, any set of retrieved of documents will always include a certain fraction of irrelevant
documents, also termed false positives. As a search attempts to capture an ever higher fraction
of relevant documents, the sensitivity of the search will decrease because the proportion of false
positives will increase. In the extreme, every relevant document can only be captured if every
irrelevant document is also captured, as depicted in Figure 899.
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Figure 8. Inverse relationship between recall and precision.
Stated another way, a high recall means you haven't missed anything but you may have a lot of
useless results to sift through (which would imply low precision). High precision means that
everything returned was a relevant result, but you might not have found all the relevant items
(which would imply low recall).100

Figure 9. An optimal balance can be achieved which is neither 100% precise nor
contains 100% recall.
An optimal balance, point C in Figure 9101, must therefore be achieved between precision (degree
of relevance of all retrieved documents) and recall (fraction of relevant documents retrieved). In
terms of patent searching, and in particular searching for relevant vaccine patents within the
100
101
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influenza vaccine landscape, one deciding on that balance point must have experience in patent
searching in general, knowledge concerning the technology involved, and an understanding of
the goal of the search. The purpose of the methodology described in the previous report and
refined in this update is to provide a framework for such a decision-making process.
A search method example that resulted in high levels of recall and low levels of precision is
semantic searching. In this search method, recall was high but precision was low. The reason
semantic searching may have been less than effective is that the boundaries that create accuracy
in a search, the keywords, were computer generated. Although it is difficult to judge the
precision levels of semantic searching based on our limited attempts, this results seem to indicate
that the keywords generated by a computer do not result in high levels of precision.
Other databases were more successful for obtaining high levels of precision. For example, when
the search string was controlled and the database being searched was efficient, the results that
were obtained were an optimal balance between precision and recall. For example, Derwent is a
pre-screened database, where language and classifications are carefully standardized. Therefore,
precision is increased due to accuracy and efficiency of searching.

Platform Services
U.S. Patent and Trademark Office102
ITTI utilized the USPTO database for classification searching, a patent search platform created
by the United States Patent and Trademark Office, which provides function to search for patents
within any of the USPTO’s classifications. The USPTO database also allows for nonclassification searching.

Thomson Innovation103
ITTI utilized Thomson Innovation, a patent search platform that integrates the best of the suite of
Thomson tools, Aureka, Delphion and MicroPatent. Thomson Innovation is a single,
integrated tool that combines intellectual property, scientific literature, business data and
news with analytic, collaboration, and altering tools in a robust platform.

TotalPatent104
ITTI also utilized TotalPatent, a LexisNexis platform, to search patents and patent
applications world-wide. TotalPatent provides several additional countries that are not
included in other platforms. Also, TotalPatent offers useful tools such as semantic searches,
the ability to search for subsidiary companies and corporate structure, and analytics.
102

http://www.uspto.gov/.
http://info.thomsoninnovation.com/.
104
http://www.lexisnexis.com/en-us/products/total-patent.page.
103

28

Sequence Searching
ITTI also performed sequence searching to corroborate the results from conventional search
methods. ITTI performed the sequence searches after searching non-patent literature in NCBI’s
PubMed.105 The non-patent literature documents were generally scientific articles containing
nucleotide and protein sequences related to the relevant technology. The sequences referenced in
the articles were inserted into GenomeQuest106 and ITTI used the BLAST algorithm107 to
perform a search that produced patents with the same or similar nucleotide or protein sequences.
The sequence searches were performed concurrently with the conventional search methods. The
sequence search results were used to corroborate results and also to ensure that ITTI was not
overlooking any patents within the relevant technology field.
Sequence searching using PubMed and GenomeQuest produces an abundance of non-patent
literature and provides a way to narrowly search for patents related to the relevant technology.
Overall sequence searching allowed ITTI to corroborate its results and revealed that ITTI had not
missed any major portions of the relevant technology. However, sequence searching produces
results narrowly confined to those nucleotide or protein sequences and thus becomes a tedious
search method if used predominantly. ITTI’s sequence searching method is thus best used as an
initial search for non-patent literature and also as a way to corroborate search results.

Deduplication Process and Collapsing into Families
The search results from ITTI’s secondary patent searches were combined to form a single list of
patent documents. The combined search results were placed into Microsoft Excel as publication
numbers and deduplicated. The number of duplicates was taken as an indication of the level of
recall. For example, a high percentage of duplicates would mean that most of the relevant results
had been identified. However, publications numbers with different file extensions, such as PCT
extensions A1, A2, and A3, would be recognized as different even though the numbers
corresponded to the same application.
A further method of deduplication employed Thompson Innovation. A publication number
search was performed and all related INPADOC family members were returned in the result set.
The data was saved as a work file. The same procedure was performed with a different team
member’s search results. One work file could be subtracted from the other, and the size of the
subtracted file would indicate the level of overlap and thus the level of recall being achieved.
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The work files could also be merged, and Innovation would automatically remove duplicates in
the merged work file.
Once a compiled list of all search results was deduplicated, the results were then collapsed by
INPADOC family to reduce the initial search results into representative patent family
documents. ITTI gave preference to US documents because these documents were easier for the
team to analyze and they tended to contain the most complete bibliographic information
available. The collapsed list was a much more manageable number of documents which the
team could efficiently code into categories. The team recognizes that the representative family
member could be a divisional application and thus would not claim the full limit of the invention.
Although this could result in an error, either towards inclusion or exclusion, time constraints
prohibited coding of every publication individually.
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Results
Relevant/Irrelevant Determination
A master of list of influenza-related documents was assembled following three complete rounds
of searching by each of the four team members.108 On the second round of searching, about 25%
of over 15,000 documents were repeated among the different members’ results. However, the
third round of searching generated only 78 new INPADOC families, compared to over 3,700
previously identified families, which was only a 2% increase in the results. Thus, the team was
confident that at least 98% of the influenza-related documents had been captured.
The results were compiled and a publication number search was performed using Innovation to
expand the families. Approximately 33,500 total documents were identified, and these results
were collapsed into almost 3,800 INPADOC patent families.109 Representative family members
were then subjected to a coding process. Publications that were irrelevant to influenza or were
outside the scope of this project were excluded. Documents were also excluded if they were
duplicates (such as an application and a patent that was issued from that application which was
not assigned properly to the same INPADOC family110), or if there was too little information in
the record to support a coding decision, such as some documents that had only a title111.
Documents were considered relevant if they specifically claimed influenza or members of the
orthomyxovirus family. Coding was done on the claims of the representative family members,
or, if no claims were available, coding was done using other family members. INPADOC family
members were given preference, but DWPI family members were used alternatively. Family
members were selected in the following order, as available: a U.S. application (assumed to have
the broadest claims), U.S. patent, a PCT application, and finally a document having claims in
English, such as a document from Great Britain or Australia. If no family members had claims
in English, foreign language claims were translated into English using Google Translate.112 If
there were no family members having claims in their records, the family was coded using a
DWPI summary of the claims, or if absolutely necessary, on the abstract alone. In the final case,
the coding was done very conservatively and the document was excluded unless it obviously
related to a prophylactic influenza A vaccine.
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In this manner, over 97% of the results were either assigned to one of the coding categories given
below or were excluded as outside the scope of this report. Many documents were relevant to
multiple categories, but each representative family was placed in only one category, that
category being the best fit for the overall focus of the document. For example, a document
claiming both a complete vaccine and the components to be assembled into that vaccine was
placed into one of the vaccine categories. Alternatively, if the document focused on the process
of making the vaccine, the document was coded to one of the method categories. In general,
there were four major categories for coding documents: vaccines, supporting technologies,
general platforms, and excluded documents. The first two categories were divided into
subcategories. The definitions and criteria for each category are given below. The Master
Coding Document can be found in Appendix A.

Coding Categorization of Patent Documents
General platforms.
A document had to specifically claim influenza in order to be considered relevant. However,
about 15% of the results claimed influenza only generally, such as in a large Markush group113 or
only in one dependent claim114. The technology described in such documents could be useful in
constructing an influenza vaccine, but could just as easily serve as a platform for vaccines
against a wide range of pathogens. These documents were considered to have a low level of
relevance. While these documents are captured and reported in Appendix B, they are not
included in any of the analysis below.
Vaccines.
Vaccines were divided into three subcategories: whole virus vaccines, subunit vaccines, and
DNA vaccines. Whole virus vaccines included live, attenuated (live but avirulent), or killed
whole virus particles. This group would also contain split (digested) but unfractionated
preparations of viruses, so that the vaccine contained all possible influenza antigens. Many of
these whole viruses were recombinant virions which contained one or more antigens from a
pandemic virus expressed by an otherwise nonpathogenic virus.
Subunit vaccines contain individual influenza antigens or a mixture of a limited number
of antigens, but less than a complete virus. The antigens could either be purified from whole
viruses or produced as recombinant versions of the native protein. The subunits could be also be
expressed by non-influenza viruses that act as a carrier for the influenza antigen or as a
secondary source of antigens to create a multivalent vaccine, such as a recombinant vaccinia
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virus carrying an influenza H5 antigen.115 The influenza antigens could also be expressed by
bacteria such as salmonella116 or by yeast.117
DNA vaccines are nucleic acid constructs which, when injected into an animal, cause
expression of an influenza antigen by host cells that take up the nucleic acid constructs. DNA
vaccines are typically very good at stimulated cell-mediated immunity, such as cytotoxic T
lymphocytes which would in turn destroy influenza-infected host cells. These nucleic acid
constructs could be either linear pieces of DNA or RNA, which are short-lived in the host, or
DNA plasmids, which can persist for a period of time.
To be considered a vaccine-related publication, the representative document must have
claimed compositions of matter having all aspects of a true vaccine: antigen(s), adjuvant (if
necessary), carriers/diluents, and a means or route of delivery. If the claims do not meet these
aspects, or were solely method claims, the family was placed in one of the supporting technology
categories. Merely terming a composition was not sufficient; the claims must have had enough
detail to describe an actual vaccine. Some allowance was made for foreign language documents
in that a broader range of terminology was accepted as a description of a vaccine. Vaccine
documents are reported in Appendix C.
Supporting Technologies.
Some documents claimed influenza in independent claims yet did not sufficiently claim a
vaccine composition for use in humans. These documents were coded as one of the supporting
technologies which are important for the construction or manufacture of vaccines. Included in
the supporting technologies subcategories are novel viruses useful in vaccines and novel subunit
constructs useful in vaccines. These documents describe the antigenic components of a vaccine,
but lack detail of carriers, adjuvants, and route of administration. Thus these two subcategories
were focused on compositions of matter.
Two other subcategories of the supporting technologies were focused more on methods utilized
in vaccine manufacture. The first such subcategory contains documents describing methods of
making vaccines, which includes procedures for purifying antigens118 and for formulating
vaccines, such as the addition of a specific adjuvant119 or preparations for intranasal delivery.120
The other subcategory was established for documents which disclosed methods of producing
virus or viral subunits. These method including nucleic acid constructs which could be used to
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produce recombinant viruses,121 cell lines which could be used to produce viruses,122 or nucleic
acid constructs encoding recombinant versions of influenza antigens.123 While the former
subcategory was mostly for method patent documents, the latter subcategory contained a mixture
of method and composition of matter claims.
A final subcategory under the heading of supporting technologies was for veterinary vaccines.
While the documents in this subcategory described complete vaccines, those vaccines were not
for use in humans, although it is possible some may have been able to be adapted for human use.
These vaccines were for birds (mostly chickens), pigs, horses, dogs, and other domesticated
animals. Such vaccines may be useful not only veterinary purposes but also to prevent
transmission of novel influenza strains to humans.
The heading of supporting technologies thus contains a broad spectrum of patent documents
covering a variety of different technologies. However, all of these documents are relevant to the
production of influenza vaccines and the prophylactic treatment of human populations. The
entire list of these documents is presented in Appendix D.
Note on the order of placement
As mentioned above, representative documents may have fit in multiple categories, but the
documents were placed in the category which was the most relevant to the overall focus of the
document. The order of placement was:
1. Whole virus vaccines
2. Subunit vaccines
3. DNA vaccines
4. Methods of making vaccines
5. Methods of producing virus or viral subunits
6. Veterinary vaccines
Documents were placed in the highest category in which the claims from that document fit.
However, if no claims were available in the record of that document or any of its family
members, the document were conservatively coded, mostly in the lower categories. If the
available record mentioned multiple pathogens, the document without claims was often placed in
the platform category.
Excluded irrelevant documents
Approximately half of the documents were excluded as irrelevant or as having insufficient
information to allow coding. The full list of these documents can be found on the Master Coding
Sheet in Appendix A, but it is useful to detail the reasons for exclusions here, to clarify the scope
of the project.
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1. Therapeutic interventions, such as small molecule medicines which inhibit viral
replication or function. Therapeutics also include interfering RNA (RNAi) molecules.
2. Means of detecting the presence of influenza virus.
3. Diagnostic methods.
4. Passive immunization.
5. Antibodies directed against influenza. These could be used in any of the above
categories. A few patent document mentioned using anti-influenza antibodies to
stimulate anti-idiotype responses, but none of those documents disclosed an anti-idiotype
monoclonal antibody that could be used to immunize humans.
6. Adjuvants, when influenza is not specifically claimed.
7. Devices, such as surgical masks to prevent infection.
8. Delivery systems for vaccines.
9. Immunization schedules, when a particular vaccine formulation is not disclosed.
10. Herbal medicines, which were common among Chinese documents.
11. Documents actually related to Haemophilus influenzae, a bacteria often present in lung
infections. Searches for the influenza virus often returned this pathogen as well.
12. Documents actually related to parainfluenza, a distantly-related virus in the
paramyxovirus family. Searches for the influenza virus often returned this pathogen as
well.
13. Documents in which influenza is used only as a tool, such as a fusion partner for other
antigens or as immunostimulatory peptides employed as adjuvants. Sometimes
recombinant influenza viruses were constructed to contain antigens for other pathogens.
While these documents did relate to anti-influenza immune responses, they are not
relevant to the generation of prophylactic immunity against pandemic influenza.
14. Documents related to seasonal influenza only, such as influenza B.
15. Quality control methods for standardizing vaccines. The team decided such documents
were too peripheral to vaccine production.
16. Sterilizing methods or devices. This includes removal of viruses from blood products
prior to transfusion, for example.
17. Computer programs used to predict antigenic epitopes, unless such epitopes were
specifically identified and claimed.
18. Dietary supplements which supposedly boosted immunity or otherwise prevented
infections.
19. Documents in which influenza was not claimed. Particularly in some general platform
technologies, influenza may be mentioned in the abstract but not in the claims.
20. Documents which were not related to influenza.

The last reason needs to be expanded upon, as a small percentage of the results had no relation to
influenza but the presence of such documents in a result set is always a concern. In some cases,
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influenza peptides were used in assays which were summarized in the Derwent abstract, but the
document was not focused on influenza. Other documents did not relate to the vaccine field in
any way. These documents may have been returned because some jurisdictions re-use patent
numbers with different file extensions, and TotalPatent mistakenly considers the two documents
to be family members. For example, CN1147316C is a patent disclosing a subunit vaccine and is
a family member with US5948410A, but CN1147316A is a patent for bricks used in walls and
floors. Other countries, such as Japan, also have confusingly similar patent numbers to describe
unrelated technologies.
Distribution of coding categories
The relative distribution of the results into the various categories is given in Table I. One-third
of the results were considered relevant as either a vaccine document or a document describing
one of the supporting technologies. Analytics was performed on these patent documents. The
remainder of the results are reported in the appendix but were not included in the analysis.
Table I. Distribution of results (3,800 families) into coding categories.
15.0%
Vaccines
(6.5%)
Whole virus vaccines
(6.7%)
Subunit vaccines
(1.9%)
DNA vaccines
19.8%
Supporting Technologies
(2.3%)
Novel viruses useful in vaccines
(2.7%)
Novel subunits useful in vaccines
(6.7%)
Method of making vaccines
(4.5%)
Method of producing virus or viral subunits
(3.7%)
Veterinary vaccines
14.7%
Platform technologies
2.3%
Excluded due to lack of information or as duplicates
48.2%
Excluded as irrelevant

Pandemic Influenza Documents
Searching was done for influenza-related patent documents which were then categorized based
on their relationship to vaccines for influenza A. Not all documents were specific as to whether
the technology could be used with pandemic influenza strains, seasonal influenza strains, or both.
The team decided to err on the side of inclusion, so that a document was considered relevant if it
mentioned influenza generally, pandemic influenza strains, or both pandemic and seasonal
strains. Only if the document was specifically limited to seasonal influenza was it excluded.
Approximately 20% of families in the vaccine category and 10% of families in the supporting
technology category referenced either pandemic or epidemic influenza in the DWPI title or
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abstract. Documents representing each family are presenting in Table II. Full information on
those documents can be found in Appendices C and D.
Table II. Documents representing a patent family referencing pandemic influenza.
Publication
Number
Vaccine Category
AU2012216357A1

Title - DWPI

Assignee/Applicant

New recombinant adenovirus vector comprises a
polynucleotide encoding at least one antigen of
an avian influenza strain, useful for producing
vaccines for eliciting an immune response
against avian or pandemic influenza

PURDUE RESEARCH
FOUNDATION | GOVERNMENT
OF THE US SECRETARY OF THE
DEPT OF HEALTH AND HUMAN
SERVICES CT S FOR DISEASE
CONTROL AND

CN101053658A

Preparing composite multi-epitope bivalent
nucleic acid vaccine for preventing H3,H9
subtype influenza virus, by obtaining a
composite multi-epitope target Epi gene, and
inserting into pIRES1neo expression vector

JIN Ning-yi,Changchun, Jilin
130062,CN

CN101450209B

New transdermal influenza immunization
multivalent vaccine comprising transdermal
agent, transdermal immune adjuvant, and
influenza multivalent vaccine antigen, useful for
immunizing Balb/c mouse, ferret, monkey, and
humans

Academy of Military Medical
Sciences of The CPLA Institute of
Microbiology and
Epidemiology,CN

CN101524538A

New influenza-pandemic influenza bivalent
combined vaccine comprises influenza
immunogen, pandemic influenza immunogen,
and vaccine adjuvant, for treating or preventing
influenza, pandemic influenza, or bird flu viral
epidemic influenza

Chengdu Kanghua Biological
Products Co. Ltd.,Chengdu,
Sichuan 610100,CN

CN101745109A

Influenza virus vaccine preparation involves
inoculating Influenza A and B influenza viruses
into allantoid cavity of ten days old thousand
healthy chick embryos to amplify influenza
viruses

Yunnan Valvax Biotechnology
Co. Ltd.,Kunming, Yunnan
650106,CN

CN101808659A

Inactivated influenza vaccine comprises beta
propiolactone inactivated whole influenza virus
and a mono- or disaccharide derivative having
specific fatty acid ester groups, as an adjuvant

NOBILON INTERNAT B V,NL
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CN101816785B

Preparing H9N2 subtype avian influenza
inactivated vaccine comprises screening,
identifying, and domesticating virus in a cell line,
and initial amplification culturing the virus in the
cell

Yangzhou Youbang
Biopharmaceutical Co. Ltd.,CN

CN101879312B

New M2e-carrier protein coupler, chemically
coupled by ectodomain M2e of influenza A
H1N1 virus M2 protein, useful for preventing
influenza

Beijing Jingyi Technology
Development Co. Ltd.,CN

CN101926994B

Immunoadjuvant used in influenza vaccine,
comprises turtle shell extract and carrier, and
has low side effect and is prepared in simple,
cost-effective and eco-friendly manner

Institute of Medical Biology
Chinese Academy of Medical
Sciences,CN | Chinese Academy
of Sciences Kunming Institute of
Botany,CN

CN101926995A

Immunoadjuvant used in influenza vaccine,
comprises Asparagus extract and carrier, and is
safe and prepared in simple, cost-effective and
eco-friendly manner

Chinese Academy of Sciences
Kunming Institute of Botany,CN
| Institute of Medical Biology
Chinese Academy of Medical
Sciences

CN102068692A

Influenza virus split vaccine comprises influenza
virus hemagglutinin (H1N1), H3N2 and B types,
CpG oligodeoxynucleotides adjuvant and
aluminum adjuvant

Beijing Minhai Biotechnology
Co. Ltd.,CN

CN102397559A

New HA218-72-carrier protein conjugate useful
for preventing or treating influenza

Beijing Jingyi Technology
Development Co. Ltd.,CN

CN1810961B

Recombinant influenza virus useful as vaccine,
involves inserting PB2, PB1, PA, M, NS and NP
coding genes from cold-adapted strain of type-A
or type-B influenza virus into eukaryotic cell
expression plasmid

INST MICROBIOLOGY &
EPIDEMIOLOGY

EP1599581A2

New attenuated influenza virus, useful as
vaccine, has altered protease cleavage site in
hemagglutinin, is not pathogenic but still
immunogenic

Transmit Gesellschaft für
Technologietransfer mbH,35394
Giessen,DE,03201700 | Philipps
Universität Marburg,35032
Marburg,DE,04124880

FR2866031B1

Viral chimer, useful to e.g. treat viral diseases,
comprises capsid and/or lipidic envelop,
defective genome, genome to serve a helper
virus and genome comprising nucleotide
sequences encoding polypeptides used in viral
antigenicity

MILLET DAVID FRANCOIS
JOSEPH
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HK1144374A0

Preparing an influenza vaccine from influenza
virus grown in a culture of a mammalian cell line
by testing the vaccine or culture for an infectious
agent that can grow in the cell line but that does
not grow in embryonated hen eggs

HK1144904A0

Eliciting or inducing a protective immune
response in a subject against a pandemic
subtype of influenza virus, comprises
administering to the subject a composition
comprising an immunogen of an endemic
influenza subtype

HK1146807A0

New monovalent influenza vaccine, useful
particularly for preventing infection by pandemic
strains, contains low dose of egg-derived antigen

HK1155639A0

Kit for raising immune response in patient for
protecting against influenza virus infection
comprises aqueous inactivated influenza vaccine

IN200703448P2

Immunogenic composition for preparing
vaccines against e.g. influenza virus comprises
influenza antigen from at least two influenza
virus strains and at least one strain associated
with pandemic outbreak and oil-in-water
emulsion adjuvant

IN200703777P4

New nucleic acid construct, comprises chimeric
promoter sequence, coding sequence, nontranslated leader sequence, and enhancer
sequence, for inducing an immune response
against influenza virus hemagglutinin (HA)
antigen

IN200704067P2

Use of an influenza virus or antigenic
preparation, and an oil-in-water emulsion
adjuvant, for inducing at least one of an
improved CD4 T-cell immune response, and an
improved B-memory cell response against the
virus
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IN200704150P2

New recombinant adenovirus vector comprises a
polynucleotide encoding at least one antigen of
an avian influenza strain, useful for producing
vaccines for eliciting an immune response
against avian or pandemic influenza

IN200801841P2

New immunogenic composition comprising an
influenza virus antigen, an oil-in-water emulsion
adjuvant and a cytokine-inducing agent, useful in
raising an immune response against influenza
virus infection in a patient

IN200801873P2

New immunogenic composition comprises split
influenza virus antigen and oil-in-water
emulsion, where the emulsion includes free
surfactant in its aqueous phase, useful as
vaccine for protecting against influenza virus
infection

IN200805247P2

New monovalent influenza vaccine composition
comprises low amount of influenza virus antigen
from an influenza virus strain that is associated
with a pandemic, useful for protecting a human
from influenza infection

IN200903238P2

New immunogenic influenza composition,
comprises an influenza virus antigen or antigenic
preparation in combination with an oil-in-water
emulsion adjuvant, useful for treating or
preventing diseases caused by influenza
infection

IN201001237P2

Eliciting or inducing a protective immune
response in a subject against a pandemic
subtype of influenza virus, comprises
administering to the subject a composition
comprising an immunogen of an endemic
influenza subtype

IN201001619P4

Inactivated influenza vaccine comprises beta
propiolactone inactivated whole influenza virus
and a mono- or disaccharide derivative having
specific fatty acid ester groups, as an adjuvant
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IN201004612P2

Kit for raising immune response in patient for
protecting against influenza virus infection
comprises aqueous inactivated influenza vaccine

IN201100348P4

Immunogenic composition, useful for treating
influenza, comprises types A and B influenza
hemagglutinin proteins

JP04031478B2

Recombinant influenza haemagglutinin
produced in baculovirus system avoids problems
of growing virus in eggs and produces stable, uncleaved protein useful in vaccines

PROTEIN SCI,JP

JP2009102416A

Recombinant influenza haemagglutinin
produced in baculovirus system avoids problems
of growing virus in eggs and produces stable, uncleaved protein useful in vaccines

PROTEIN SCIENCES

JP2011519828A

New flagellin amino acid sequences for treating
e.g. influenza virus infection comprises specific
deletion and replacement constructs having
sequence identity to specific flagellin sequences,
where sequences activate toll-like receptor-5

KR1999022028A

Recombinant influenza haemagglutinin
produced in baculovirus system avoids problems
of growing virus in eggs and produces stable, uncleaved protein useful in vaccines

KR2010045436A

New isolated attenuated influenza virus strain
comprises internal genome segments of
A/PR/8/34(H1N1) and surface antigens
hemagglutinin and neuraminidase of
A/Aichi/2/68(H3N2), useful as vaccines against
influenza virus infections

MX290169B

Use of an influenza virus or antigenic
preparation, and an oil-in-water emulsion
adjuvant, for inducing at least one of an
improved CD4 T-cell immune response, and an
improved B-memory cell response against the
virus
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BIOTRION INC.

MX293233B

Stabilizing influenza vaccine composition
comprises diluting liquid bulk composition,
subjecting regular droplets to freezing to form
frozen regular spherical micropellets or particles,
and drying

PH12009500128A

New monovalent influenza vaccine composition
comprises low amount of influenza virus antigen
from an influenza virus strain that is associated
with a pandemic, useful for protecting a human
from influenza infection

RU2077581C1

New vaccine strain A (47) Texas-91(2)6 (H1N1)
can be used in medicinal virology, for production
of live influenza vaccine for children

NIIEX MEDITSINY RAMN

RU2077582C1

New vaccine strain A (17) Shangdong (93) 3/5
(H3N2) can be used in medicinal virology, for
production of live influenza vaccine for adults

NIIEX MEDITSINY RAMN

RU2099086C1

Prevention of influenza epidemics in children by
intranasal administration of live attenuated cold
adapted vaccine

NIIEX MEDITSINY RAMN

RU2110277C1

New strain A(17) of influenza virus Johannesburg
(94) 1 (H3 N2) GISK N 391 used for production of
live intranasal influenza vaccine for adults

NI SKIJ I EHKSPERIMENTAL | NOJ
MEDITSINY RAMN

RU2110278C1

New strain A(17) of influenza virus Johannesburg
(94) 1 (H3 N2) GISK N 392 used for production of
live intranasal influenza vaccine for children

NOJ MEDITSINY RAMN | NI SKIJ
I EHKSPERIMENTAL

RU2127757C1

Strain a/47/nanchang/95/13 (h3n2) for
production of live antiinfluenza intranasal
vaccine for children

NOJ MEDITSINY RAMN | NI SKIJ
I EHKSPERIMENTAL

RU2128223C1

Strain a/17/nanchang/95/4 (h3n2) for
production of living an antiinfluenza intranasal
vaccine for adults

NOJ MEDITSINY RAMN | NI SKIJ
I EHKSPERIMENTAL

RU2144955C1

Strain of influenza virus a/17/pert/95/29(H1N1)
for production of live anti-influenza intranasal
vaccine for adult humans

NII EHKSPERIMENTAL | NOJ
MEDITSINY RAMN

RU2159809C1

Influenza virus strain a/47/sydney/97/14 (h3n2)
for production of live influenza intranasal
vaccine for babies

NII EHKSPERIMENTAL | NOJ
MEDITSINY RAMN
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RU2159810C1

Influenza virus strain a/47/peking/95/35 for the
production of live influenza intranasal vaccine
for babies

NII EHKSPERIMENTAL NOJ
MEDITSI

RU2159811C1

Influenza virus strain a/17/peking/95/25 (h1n1)
for production of live influenzal intranasal
vaccine for adults

NII EHKSPERIMENTAL | NOJ
MEDITSINY RAMN

RU2183672C1

A novel strain of influenza virus A/17/New
Caledonia/99/145 (H1N1) for production of live
anti-influenza, intranasal vaccine for adults

NII EHKSPERIMENTAL | NOJ
MEDITSINY RAMN

RU2185437C1

Strain of influenza virus a/47/new
caledonia/99/156 (H1N1), useful for production
of live influenza intranasal vaccine for children

NII EHKSPERIMENTAL | NOJ
MEDITSINY RAMN

RU2248394C1

New influenza virus strain A/47/panama/99/234
(H3N2) for producing a live anti-influenza
intranasal vaccine for children

RU2248395C1

New strain A/17/Panama/99/242 (H3N2) for
producing a live anti-influenza intranasal vaccine
for adults

RU2266329C1

Strain for production of living influenza
intranasal vaccine for adults and infants

RU2315101C2

Vaccine strain of influenza virus
a/17/california/04/6 (h3n2) and attenuation
donor a/leningrad/134/17/k7/57 (h2n2) for its
preparing

RU2319744C2

Strain of influenza virus, gisk 147, used for
preparing influenza intranasal vaccine for adults
and children

GU NII EHKSPERIMENTAL NOJ
MEDI

RU2416640C1

Vaccine strain of a/17/brisbane/07/1 (h3n2)
influenza virus for preparing live influenza
intranasal vaccine for adults and children

UCHREZHDENIE ROSSIJSKOJ
AKADEMII MED NAUK NII
EHKSPERIMENTAL NOJ
MEDITSINY SEV ZAP OTDEL
RAMN NIIEHM

RU2416641C1

Vaccine strain of a/17/brisbane/07/28 (h1n1)
influenza virus for preparing live influenza
intranasal vaccine for adults and children

UCHREZHDENIE ROSSIJSKOJ
AKADEMII MED NAUK NII
EHKSPERIMENTAL NOJ
MEDITSINY SEV ZAP OTDEL
RAMN NIIEHM
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RU2422518C1

Vaccine strain of a/17/solomon islands/06/9
(h1n1) influenza virus for preparing live
influenza intranasal vaccine for adults and
children

UCHREZHDENIE ROSSIJSKOJ
AKADEMII MED NAUK NII
EHKSPERIMENTAL NOJ
MEDITSINY SEV ZAP OTDEL
RAMN NIIEHM

RU2422519C1

Vaccine strain of b/60/florida/04/181 influenza
virus for preparing live influenza intranasal
vaccine for adults and children

UCHREZHDENIE ROSSIJSKOJ
AKADEMII MED NAUK NII
EHKSPERIMENTAL NOJ
MEDITSINY SEV ZAP OTDEL
RAMN NIIEHM

SU1571067A1

Influenza virus strain used in prepn. of living
influenza vaccine for children and adults

VNII GRIPPA | LE NII VAKTSIN
SYVOROTOK | GNII
STANDARTIZAT KONTROL

SU1655985A1

Live intranasal vaccine against influenza gp. A
virus for children involves using specified
recombinant strain of virus to increase efficiency

NIIEX MEDITSINY AMN SSSR |
MO NII VIRUSNYKH
PREPARATOV | VNII GRIPPA |
GNII STANDARTIZAT KONTROL

TW200628611A

New nucleic acid construct, comprises chimeric
promoter sequence, coding sequence, nontranslated leader sequence, and enhancer
sequence, for inducing an immune response
against influenza virus hemagglutinin (HA)
antigen

TW200700078A

Immunogenic composition for preparing
vaccines against e.g. influenza virus comprises
influenza antigen from at least two influenza
virus strains and at least one strain associated
with pandemic outbreak and oil-in-water
emulsion adjuvant

TW200700079A

Immunogenic composition for preparing
vaccines against e.g. influenza virus comprises
influenza antigen from at least two influenza
virus strains and at least one strain associated
with pandemic outbreak and oil-in-water
emulsion adjuvant

TW200722101A

Immunogenic composition for preparing
vaccines against e.g. influenza virus comprises
influenza antigen from at least two influenza
virus strains and at least one strain associated
with pandemic outbreak and oil-in-water
emulsion adjuvant
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US20060121447A1

New subfragment of an RNA sequence coding
for a neuroaminidase protein NAy, useful in
preparing a vaccine against avian influenza virus
infection with specific epidemic strain HxNy

US20080254065A1

Vaccine for protecting a human patient against
infection by a human influenza virus strain,
comprises an antigen from an avian influenza
virus strain that can cause highly pathogenic
avian influenza

US20100008952A1

Novel replication-defective adenoviral vector
comprising nucleic acid encoding influenza A
polypeptide, useful for inducing immune
response in subject, and as vaccine to reduce
risk of infection by influenza

US20100099745A1

Inhibiting viral infection in a subject by
administering recombinant adenovirus vector
comprising a nucleic acid encoding a caspase
recruitment domain from melanoma
differentiation-associated gene 5 or retinoic acid
inducible gene I

US20100129399A1

New linear expression construct that is free of
any amplification and/or selection sequences,
useful for preparing a composition for treating
or preventing infectious diseases, e.g., avian
influenza virus infection

AVIR Green Hills Biotechnology
Research Development Trade
AG,Wien,AT

US20100166769A1

Preparing influenza virus-like particle used as
vaccine, by inserting recombinant DNA with
influenza hemagglutinin and neuraminidase
sequences into Vero cell with influenza M1 and
M2 sequences and culturing obtained
coexpression cell

Academia Sinica,Taipei,TW

US20100189745A1

Reassortant influenza virus useful as vaccine for
eliciting immune response comprises internal
gene segment derived from first influenza virus
A subtype, and hemagglutinin and
neuraminidase genes from the influenza virus
subtype

BAXTER INTERNATIONAL
INC.,Deerfield,IL,US | BAXTER
HEALTHCARE S.A.,Glattpark
(Opfikon),CH
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CHIRON
CORPORATION,Emeryville,CA,US

US20100221349A1

New nucleic acid construct, comprises chimeric
promoter sequence, coding sequence, nontranslated leader sequence, and enhancer
sequence, for inducing an immune response
against influenza virus hemagglutinin (HA)
antigen

Powderject Vaccines Inc. |
Powdermed Limited

US20100291146A1

Eliciting or inducing a protective immune
response in a subject against a pandemic
subtype of influenza virus, comprises
administering to the subject a composition
comprising an immunogen of an endemic
influenza subtype

CSL Limited,Victoria,AU

US20110097418A1

Immunogenic composition, useful for treating
influenza, comprises types A and B influenza
hemagglutinin proteins

VARIATION BIOTECHNOLOGIES
INC.,Gatineau,QC,CA

US20110129497A1

Manufacturing a composition comprising
directed-sequence polymers (DSPs) comprises
selecting an amino acid sequence of an epitope
of an antigen associated with a disease, and
synthesizing a cassette of the DSPs

Peptimmune
Inc.,Cambridge,MA,US

US20110150912A1

New live attenuated avian influenza virus useful
in vaccine for preventing epidemic and
pandemic influenza, comprises basic 2 protein
gene and basic 1 protein gene

US20110180430A1

New immunogenic composition comprising an
NOVARTIS VACCINES AND
influenza virus antigen, an oil-in-water emulsion DIAGNOSTICS SRL,Siena,IT,IT
adjuvant and a cytokine-inducing agent, useful in
raising an immune response against influenza
virus infection in a patient

US20110229518A1

Use of nucleotides encoding influenza proteins
e.g. haemagglutinin with few or no glycosylation
sites for manufacturing immunogenic
composition or vaccine component against
present day and coming influenza A infections in
humans and pigs

Statens Serum
Institut,Copenhagen S,DK

US20110262481A1

New reassortant influenza-A virus comprising
gene segments of seasonal or pandemic strain
origin, a polymerase basic protein-1 gene
segment, and a polymerase gene segment,
useful e.g. as vaccine to prevent influenza virus
infection

AVIR GREEN HILLS
BIOTECHNOLOGY RESEARCH
DEVELOPMENT TRADE
AG,Vienna,AT
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US20110287054A1

Immunogenic composition for preparing
vaccines against e.g. influenza virus comprises
influenza antigen from at least two influenza
virus strains and at least one strain associated
with pandemic outbreak and oil-in-water
emulsion adjuvant

US20110305748A1

Composition for immunizing subject against pre- IMMUNE DESIGN
pandemic influenza virus comprises recombinant CORP.,Seattle,WA,US
hemagglutinin from pre-pandemic influenza
virus, and adjuvant comprising disaccharide
having reducing/non-reducing terminus e.g.
glucosyl

US20120009215A1

New hemagglutinin and/or neuraminidase
variant, useful for stimulating an immune
response against influenza virus, or for
prophylactic or therapeutic treatment of a viral
infection

US20120034264A1

New 6:2 reassortment influenza virus, useful as
a vaccine for stimulating the immune system of
an individual or for treating or preventing a viral
infection in a subject

MedImmune
LLC,Gaithersburg,MD,US

US20120064110A1

Dosage form, useful e.g. for the prophylaxis of
influenza virus infection, preferably influenza A
virus infection, comprises synthetic nanocarriers
coupled to peptides that are obtained from
human influenza A virus hemagglutinin

Selecta Biosciences
Inc.,Watertown,MA,US

US20120064115A1

Recombinant virus-like particle used as vaccine
comprises at least two different
epitopes/proteins containing epitopes selected
from different viral strains/serotypes of same
virus and/or different viral strains specific for
different hosts

US20120207786A1

Use of influenza virus like particle comprising
specified influenza virus protein and specified
influenza virus hemagglutinin and
neuraminidase proteins in the preparation of
vaccine for inducing substantial immunity to
influenza virus
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GlaxoSmithKline Biologicals s.a.

NOVAVAX INC.,Rockville,MD,US

US20120219584A1

Immunogen comprises nucleic acid molecule
encoding a protein with influenza A subtype H1
hemagglutinin glycan-shielded receptor binding
domain A region and influenza A subtype H1
hemagglutinin antigenic site, where site is not
within region

US20120219586A1

Adjuvanted influenza vaccine formulation, useful
for prophylaxis of influenza infection or disease
in subject, comprises peptidoglycan
microparticles, and influenza virus antigen or its
antigenic preparation

US20120244185A1

New chimeric adenoviral expression vector
comprising an expression cassette containing
promoters useful for eliciting an immune
response (mucosal immune response) against
H1N1 influenza in mammals in mammals
(human)

US20120269852A1

Influenza vaccine for immunizing patient against
influenza virus infection comprises combination
of detoxified or non-toxic mutant of subunit A of
AB type exotoxin, aluminum salt, and influenzaspecific antigen

US5948410A

New influenza surface antigen vaccine
propagated on animal cell culture used to
produce e.g. human, swine, equine and avian
influenza vaccines avoids disadvantages
associated with culturing on embryonated
chicken eggs

Duphar International Research
B,Weesp,NL

US6800288B2

Recombinant NS gene of an influenza A virus
comprising a functional RNA binding domain and
a gene sequence modification after nucleotide
position 400 of the NS1 gene segment, useful for
producing a live attenuated influenza virus
vaccine

Polymun Scientific
Immunbiologische Forschung
GmbH,Vienna,AT

US7238349B1

New monovalent influenza vaccine, useful
SmithKline Beecham Biologicals
particularly for preventing infection by pandemic s.a.,Rixensart,BE | Saechsisches
strains, contains low dose of egg-derived antigen Serumwerk Dresden,Dresden,DE
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THE UNITED STATES OF
AMERICA as represented by THE
SECRETARY DEPARTMENT OF
HEALTH,Bethesda,MD,US

Vaxart Inc.,San Francisco,CA,US

US7521220B2

Producing an influenza virus or influenza viral
protein for use as a vaccine by providing a cell
with a sequence encoding a gene product of an
adenoviral E1 gene and harvesting the influenza
virus from the suitable medium or the cell

Crucell Holland B.V.,Leiden,NL

US8119337B2

Preparing an influenza vaccine from influenza
virus grown in a culture of a mammalian cell line
by testing the vaccine or culture for an infectious
agent that can grow in the cell line but that does
not grow in embryonated hen eggs

GREGERSEN JENS-PETER

US8163545B2

New recombinant adenovirus vector comprises a
polynucleotide encoding at least one antigen of
an avian influenza strain, useful for producing
vaccines for eliciting an immune response
against avian or pandemic influenza

United States of America as
represented by the Secretary of
the Department of Health and
Human Services Centers for
Disease Control and
Prevention,Washington,DC,US |
Purdue Research
Foundation,West
Lafayette,IN,US

US8288090B2

Preventing or treating infection caused by
influenza A H1N1, H1, H2, H3, H5 or H7, involves
delivering nucleic acid molecule encoding
hemagglutinin or neuraminidase from pandemic
influenza to subject

Statens Serum
Institut,Copenhagen S,DK

VN22532A

New immunogenic influenza composition,
comprises an influenza virus antigen or antigenic
preparation in combination with an oil-in-water
emulsion adjuvant, useful for treating or
preventing diseases caused by influenza
infection

VN23203A

New monovalent influenza vaccine composition
comprises low amount of influenza virus antigen
from an influenza virus strain that is associated
with a pandemic, useful for protecting a human
from influenza infection
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WO2007065967A1

New vaccine composition containing HN antigen
pairs of influenza A virus targeted against
recombinant H5N2 type of influenza virus, useful
for vaccinating against influenza A virus

REMEDAL OY,FI | HEINO
Pekka,FI

WO2011138032A3

Immunogenic composition useful for inducing a
protective immune response to an influenza
infection in a mammal, comprises one or more
peptides

MAKSYUTOV Amir,RU |
ARTEMEV Timur,GB |
ANTONETS Denis,RU |
BAKULINA Anastasia,RU |
MAKSYUTOV Rinat,RU

WO2012114323A1

Improving protective effect of seasonal or
pandemic influenza vaccine, comprises
vaccination of subject, prior to, or together with,
administration of seasonal or pandemic vaccine,
with synthetic or recombinant multimeric
polypeptide

BEN-YEDIDIA Tamar,IL |
BIONDVAX PHARMACEUTICALS
LTD.,IL | LOWELL George H.,IL

Supporting Technologies Category
AU2011202991A8
New influenza hemagglutinin or neuraminidase
variant polypeptide, useful in preparing a
composition for treating or preventing infection
caused by influenza virus

US GOVERNMENT |
MEDLMMUNE LLC

AU2011253998A1

Replicating virus, e.g. adenoviruses,
hepadnaviruses, or herpes viruses, in avian
embryonic derived stem cells Ebx, useful as
vaccine, comprises infecting cells with the virus,
culturing infected cells, and harvesting the virus

VIVALIS

AU733191B2

Recombinant influenza haemagglutinin
produced in baculovirus system avoids problems
of growing virus in eggs and produces stable, uncleaved protein useful in vaccines

PROTEIN SCIENCES CORP

CN101560503B

New influenza A virus Vero cell adapted strain
named A/Yunnan/1/2005Va (H3N2), where the
preserving number of the strain is CCTCC No:
V200514, useful for preparing a Vero cell
adapted strain of the epidemic strain

INST MEDICAL BIOLOGY
CHINESE ACAD MEDICA,CN
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CN101897966A

Cynomorium songaricum immunological
adjuvant useful in influenza vaccine, comprises
Cynomorium songaricum extract and a carrier

Chinese Academy of Sciences
Kunming Institute of Botany,CN
| Institute of Medical Biology
Chinese Academy of Medical
Sciences

CN101899418A

New isolated avian influenza virus comprising
RNA in its genome, useful in vaccine for
preventing avian influenza virus

Shanghai Centre for Animal
Disease Control and
Prevention,CN

CN101926994B

Immunoadjuvant used in influenza vaccine,
comprises turtle shell extract and carrier, and
has low side effect and is prepared in simple,
cost-effective and eco-friendly manner

Institute of Medical Biology
Chinese Academy of Medical
Sciences,CN | Chinese Academy
of Sciences Kunming Institute of
Botany,CN

CN101926995A

Immunoadjuvant used in influenza vaccine,
comprises Asparagus extract and carrier, and is
safe and prepared in simple, cost-effective and
eco-friendly manner

Chinese Academy of Sciences
Kunming Institute of Botany,CN
| Institute of Medical Biology
Chinese Academy of Medical
Sciences

CN102038949A

Inactivated quad vaccine useful for
pharmaceutical applications comprises
inactivated Newcastle disease virus, chicken
infectious bronchitis virus, chicken egg drop
syndrome virus, bird flu virus (H9 subtype), and
adjuvant

Qingdao Yebio Bioengineering
Co. Ltd.,CN

CN102068695B

Qingdao Yebio Bioengineering
Co. Ltd.,CN

CN102078605A

Influenza vaccine produced using infected Vero
cell by preparing virus liquid vaccine by cleaning
Vero cells, adding virus into maintenance
medium, adding pancreatin to obtain virus
supernatant and purifying liquid vaccine

Jilin Yatai Bio-pharmaceutical
Co. Ltd.,CN

CN102139104A

Inactivated trivalent vaccine, useful for
Newcastle disease virus, avian influenza and
infectious bursal disease virus causing diseases,
comprises e.g. inactivated LaSota strain of
Newcastle disease virus and YBF003 strain

Qingdao Yebio Bioengineering
Co. Ltd.,CN
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CN102293743A

Lipid microsphere emulsion useful for treating
pandemic influenza virus in children, comprises
pharmaceutical grade oil, zwitterionic/non-ionic
surfactant composition, antigen associated with
pandemic influenza and aqueous solution

Liaoning Chengda Biotechnology
Co. Ltd.,CN

CN102397540A

A type avian influenza recombinant phage
vaccine, comprises recombinant T7 phage as
antigen

Jiangsu Academy of Agricultural
Sciences,CN

CN102406931A

Preparing pandemic influenza virus split vaccine
comprises culturing NIBRG-14, inactivating by
adding an inactivator containing e.g. an
alkylating agent, filtering and concentrating virus
liquid, purifying and freeze-drying vaccine
product

Chengdu Kanghua Biological
Products Co. Ltd.,CN

CN1313605C

Gene recombinant fowl influenza virus D3/FR2/6 and its construction method

Yangzhou University

CN1644686B

High yield strain of mammalian influenza virus,
useful in preparing vaccine strains of influenza A

INST BEIJING VIRAL DISEASE
CONTROL & PRE

EP1534845A1

Rescuing attenuated and/or recombinant
orthomyxovirus, useful for the manufacture of
live, attenuated vaccine, comprises delivering
the resulting recombinant baculovirus genome
to a mammalian host cell by transduction

Polymun Scientific
Immunbiologische Forschung
GmbH,1190 Wien,AT,01690530

EP2484757A1

Producing alpha-Gal expressing virus, e.g.
influenza viruses, by introducing alpha 1,3galactose transferase gene into cell, inoculating
virus into cell system and culturing viral infected
cell system to obtain virus

National University Corporation
Obihiro University of Agriculture
and Veterinary
Medicine,Obihiro-shi, Hokkaido
080-8555,JP,100825962 |
Incorporated Administrative
Agency National Agriculture and
Food Research
Organization,Ibaraki 3058517,JP,101317142

EP2491117A1

Preparing virus e.g. rotavirus, used e.g. as
vaccine, comprises transfecting culture of host
cells with expression construct encoding viral
RNA molecule, adding cells to the transfected
cells, and culturing mixture of cells to produce
virus

Novartis AG,4056
Basel,CH,101062816

GB660109A

AMERICAN CYANAMID CO
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IN201001689P4

Producing influenza virus, useful for producing
vaccine against influenza, comprises
administering a vaccine against influenza to
chickens, activating embryogenesis in eggs of
chicken, infecting eggs with influenza and
harvesting virus

IN201005447P4

Stabilizing influenza vaccine composition
comprises diluting liquid bulk composition,
subjecting regular droplets to freezing to form
frozen regular spherical micropellets or particles,
and drying

IN201104719P2

Host cell useful for producing recombinant virus
strains comprises expression construct encoding
viral RNA molecule, where expression of the
RNA molecule is controlled by pol I promoter
which is not endogenous to host cell's
taxonomic order

JP03918949B2

Recombinant influenza haemagglutinin
produced in baculovirus system avoids problems
of growing virus in eggs and produces stable, uncleaved protein useful in vaccines

PROTEIN SCI

JP2007314538A

Recombinant influenza haemagglutinin
produced in baculovirus system avoids problems
of growing virus in eggs and produces stable, uncleaved protein useful in vaccines

PROTEIN SCIENCES

KR1998081114A

New influenza surface antigen vaccine
propagated on animal cell culture used to
produce e.g. human, swine, equine and avian
influenza vaccines avoids disadvantages
associated with culturing on embryonated
chicken eggs

KR593235B1

New influenza surface antigen vaccine
propagated on animal cell culture used to
produce e.g. human, swine, equine and avian
influenza vaccines avoids disadvantages
associated with culturing on embryonated
chicken eggs
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DUPHAR INTERNATIONAL
RESEARCH B.V.

MX2009009565A

New recombinant protein comprising
ITESM
hemagglutinin of influenza virus A H1N1-2009
expressed in Escherichia coli, used as a vaccine
or the main active ingredient of a vaccine against
influenza A H1N1-2009

MX207194B

New influenza surface antigen vaccine
propagated on animal cell culture used to
produce e.g. human, swine, equine and avian
influenza vaccines avoids disadvantages
associated with culturing on embryonated
chicken eggs

RU2031941C1

Strain of virus A(H1N1) for prodn. of live
intranasal influenza vaccine based on the
epidemic virus A/Leningrad/92/89 (H1N1)

NII GRIPPA RAMN

RU2033424C1

Strain of influenza A (H3N2) virus used in prodn.
of live intranasal vaccine for children and adults

NII GRIPPA RAMN

RU2065498C1

Strain Shangdong for prodn. of live influenza
intranasal vaccine for children is useful in public
health for prevention of influenza epidemics in
children of age 3-14

NIIEX MEDITSINY RAMN

RU2078818C1

Viral strain used in preparation of active
influenza vaccine is polymorphic strain used in
intranasal influenza vaccine for adults

NIIEX MEDITSINY RAMN

RU2078820C1

Strain A/47/Peking/92/3 (H3N2) GISK No. 104 is
polymorphic and used for live intranasal
influenza vaccine used by children

NIIEX MEDITSINY RAMN

RU2084524C1

Influenza A virus strain A/17
Texas/91/1/3(H1N1) Gisk No. 102 is used in the
manufacture of live, intranasal influenza vaccine
for adults

NIIEX MEDITSINY RAMN

RU2159812C1

Influenza virus strain a/17/sydney/97/76 (h3n2)
for production of live influenzal intranasal
vaccine for adults

NII EHKSPERIMENTAL | NOJ
MEDITSINY RAMN

RU2285723C2

Influenza virus strain A/Wyoming/3/03 (H3N2)
for production of living influenza intranasal
vaccine for infants and adults

GU NII EHKSPERIMENTAL NOJ
MEDI

RU2307161C2

Influenza virus strain for living influenza
intranasal vaccine for infants and adults

GU NII EHKSPERIMENTAL NOJ
MEDI

RU2307162C1

Influenza virus strain for influenza intranasal
vaccine for infants and adults

GU NII EHKSPERIMENTAL NOJ
MEDI
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RU2413765C1

Vaccine strain of flu virus
a/17/california/2009/38 (h1n1) for profuction of
live influenza intranasal vaccine for adults and
children

UCHREZHDENIE ROSSIJSKOJ
AKADEMII MED NAUK NII
EHKSPERIMENTAL NOJ
MEDITSINY SEV ZAP OTDEL
RAMN NIIEHM

RU2428476C1

Reassortant rn a9-swine a(h7n1) influenza virus
strain for neuraminidase antibody assay in
influenza infection and vaccination

UCHREZHDENIE ROSSIJSKOJ
AKADEMII MED NAUK NII
EHKSPERIMENTAL NOJ
MEDITSINY SEV ZAP OTDEL
RAMN NIIEHM

RU2457243C1

Cultivated hybrid cell strain of mouse mus.
Musculus-1e7 producer of monoclonal antibody
immunoresponsive to haemagglutinin protein of
pandemic influena virus a/iivmoscow/01/09(h1n1)sw1

FEDERAL NOE G BJUDZHETNOE
UCHREZHDENIE NII
VIRUSOLOGII IM D I
IVANOVSKOGO MIN
ZDRAVOOKHRANENIJA I SO

RU2457245C1

Reassortant rem8-vaccine strain of suptype h1n1
influenza a virus What is offered is a vaccine
strain of A ReM8 (H1N1) virus deposited in the
State Collection of Viruses No. 2632

FEDERAL NOE G BJUDZHETNOE
UCHREZHDENIE NII
VIRUSOLOGII IM D I
IVANOVSKOGO MIN
ZDRAVOOKHRANENIJA I SO

RU2458124C2

New strain of influenza A virus subtype H3N2
useful for producing composition containing
inactivated influenza virus for treating influenza

FEDERAL NOE G BJUDZHETNOE
UCHREZHDENIE NII GRIPPA MIN
ZDRAVOOKHRANENIJA I
SOTSIAL NOGO RAZVITIJA RF

SU1003539A1

Influenza virus strain A-17-42-3 H3N2 is used for
prodn. of live influenza vaccine

POLEZHAEV F I |
ALEKSANDROVA G I |
BUDILOVSKIJ G N |
GARMASHOVA L M | KOVAL T A
| GRUNIS A M | KLIMOV A I |
SLEPUSHKIN A N | MEDVEDEVA
T E | GENDON YU Z

SU1219644A1

Influenza virus strain a-f-59-1 is used for prepn.
of inactive anti-influenza vaccine.

NIIEX MEDITSINY | MO NII
VIRUSNYKH PREPARATOV | LE
NII VAKTSIN SYVOROTOK

SU1838404A3

Influenza A virus strain H3N2 is used for the
prodn. vaccines for children which are
administered nasally, is useful for the prevention
of influenza epidemics in children

NIIEX MEDITSINY AMN SSSR

SU833260B

Prodn. of vaccine strain of influenza virus by
crossing virulent and heat sensitive viral strains
for high biological stability and immunogenic
activity
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TW570803A

New influenza surface antigen vaccine
propagated on animal cell culture used to
produce e.g. human, swine, equine and avian
influenza vaccines avoids disadvantages
associated with culturing on embryonated
chicken eggs

US20090202589A1

Fermenter vessel for culturing cells and for
preparation of virus vaccine, comprises view
port provided in outside wall for inspecting
processes within vessel volume, and heating
device on transparent member of view port

US20090326978A1

Combination anti-viral therapy stockpiling
method for e.g. pandemic influenza, involves
coordinating storage of therapeutic doses of
antiviral agents to enable shipment of
therapeutic doses within preset hours for each
other

US20110177121A1

New composition comprises an immunogenic
epitope of influenza that is not
immunodominant as in a wild type virus, useful
for inducing an immune response against
influenza

BIOLOGICAL MIMETICS
INC.,Frederick,MD,US

US20110212129A1

Producing influenza virus, useful for producing
vaccine against influenza, comprises
administering a vaccine against influenza to
chickens, activating embryogenesis in eggs of
chicken, infecting eggs with influenza and
harvesting virus

SANOFI PASTEUR S.A.,Lyon,FR |
MERIAL LIMITED,Duluth,GA,US

US20110217330A1

Degrading host cell nucleic acids associated with
virus or its viral antigen produced by cell culture,
useful to e.g. treat influenza infection, comprises
degrading the nucleic acids with an
endonuclease or a DNA alkylating agent

US20110243987A1

Immunizing a human against influenza virus
infection by selecting a human who was
previously vaccinated with a monovalent first
vaccine composition, and administering a
second vaccine composition comprising an
influenza virus antigen
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GlaxoSmithKline Biologicals s.a.

US20120189656A1

Host cell useful for producing recombinant virus
strains comprises expression construct encoding
viral RNA molecule, where expression of the
RNA molecule is controlled by pol I promoter
which is not endogenous to host cell's
taxonomic order

US20120219587A1

Producing split influenza virus preparation used
for pharmaceutical composition for preventing
and/or treating diseases caused by influenza, by
fractionating preparation, adding Triton X-100 to
preparation and filtering preparation

US20120294879A1

New polypeptide comprising lysosomeassociated membrane protein-1 (LAMP-1)
luminal sequence, a segment of influenza A
protein, and LAMP transmembrane and
cytoplasmic tail, useful in e.g. immunizing
human against human influenza A virus

NATIONAL UNIVERSITY OF
SINGAPORE,Singapore,SG | THE
JOHNS HOPKINS
UNIVERSITY,Baltimore,MD,US

US4206287A

Influenza virus mutant repeated culture and
isolation immuno vaccins against future virus
mutants

Agence Nationale de
Valorisation de la Recherche
(ANVAR),Neuilly sur Seine,FR

US6245532B1

Expressing a protein e.g. recombinant influenza
virus hemagglutinin comprising using a vector
encoding a polypeptide comprising a baculovirus
signal peptide and a baculovirus expression
system is useful as a multivalent influenza
vaccine

Protein Sciences
Corporation,Meriden,CT

US8148132B2

Replicating virus, e.g. adenoviruses,
hepadnaviruses, or herpes viruses, in avian
embryonic derived stem cells Ebx, useful as
vaccine, comprises infecting cells with the virus,
culturing infected cells, and harvesting the virus

Vivalis,Roussay,FR

US8163545B2

New recombinant adenovirus vector comprises a
polynucleotide encoding at least one antigen of
an avian influenza strain, useful for producing
vaccines for eliciting an immune response
against avian or pandemic influenza

United States of America as
represented by the Secretary of
the Department of Health and
Human Services Centers for
Disease Control and
Prevention,Washington,DC,US |
Purdue Research
Foundation,West
Lafayette,IN,US
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US8282937B2

New reassortant influenza virus, useful in
preparing a vaccine comprising the reassortant
influenza virus for preventing influenza virus
infection

VN24155A

Producing influenza virus, useful for producing
vaccine against influenza, comprises
administering a vaccine against influenza to
chickens, activating embryogenesis in eggs of
chicken, infecting eggs with influenza and
harvesting virus

WO2008138120A1

Assessing the anti-influenza effect of an agent of
interest by incubating the particles with cells
capable of infection, and comparing the
infection rate of the virus-like particles in the
presence and absence of the agent

UNIVERSITY OF MANITOBA,CA |
HER MAJESTY THE QUEEN IN
RIGHT OF CANADA AS
REPRESENTED BY THE MINISTER
OF HEALTH,CA | YAO Xiojian,CA
| AO Zhujun,CA | KOBINGER
Gary,US | KOBASA Darwin,CA

WO2011133997A1

Use of gamma-irradiated influenza virus
comprising Chalmers strain backbone of specific
proteins for treating influenza virus infection,
and for inducing cross-protective immunity
against multiple influenza virus subtypes in a
subject

GAMMA VACCINES PTY
LIMITED,AU | MULLBACHER
Arno,AU | ALSHARIFI
Mohammed,AU | HIRST Tim,AU

WO2012009790A1

Use of second unique hemagglutinin and
pathogen e.g. HIV1 protein for inducing a crossprotective antibody response in a subject that
has been previously subjected to a first unique
hemagglutinin and pathogen protein

SCHRADER John W.,CA

WO2012050229A1

New recombinant vaccinia virus used in
pharmaceutical composition for preventing
and/or treating H5N1 virus and H1N1 virus,
comprises expression promoter and
complementary DNA encoding highly pathogenic
avian influenza A (H5N1) virus

TOKYO METROPOLITAN
INSTITUTE OF MEDICAL
SCIENCE,JP | KIDA Hiroshi |
MURAKAMI Toshio,JP | YASUI
Fumihiko,JP | KOHARA
Michinori,JP | NATIONAL
UNIVERSITY CORPORATION
HOKKAIDO UNIVERSITY,JP | THE
CHEMO-SERO-THERAPEUTIC
RESEARCH INSTITUTE,JP |
SAKODA Yoshihiro
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The Regents of the University of
Michigan,Ann Arbor,MI,US

WO2012088428A1

New virus-like particle comprising a recombinant
influenza virus hemagglutinin protein, useful for
inducing substantial immunity to an influenza
virus infection, and for treating and/or
preventing influenza infection

ZA201001480A

Producing influenza virus, useful for producing
vaccine against influenza, comprises
administering a vaccine against influenza to
chickens, activating embryogenesis in eggs of
chicken, infecting eggs with influenza and
harvesting virus

ZA201006225A

Stabilizing influenza vaccine composition
comprises diluting liquid bulk composition,
subjecting regular droplets to freezing to form
frozen regular spherical micropellets or particles,
and drying

NOVAVAX INC.,US | SMITH
Gale,US | LIU Ye,US | MASSARE
Michael,US | SINGHVI Rahul,US

GenomeQuest findings
The ITTI team used genome quest for this patent landscape report according to the methodology
previously described. Find sequences from PubMed proved to be an arduous task as many of the
relevant articles did not disclose sequence that we could use for a GenomeQuest search. As
such, few sequences were found through PubMed.
Additionally the ITTI team pulled sequences directly from patents whenever they were disclosed
within the document. However, the occurrence of sequences disclosure within a patent
document was quite rare and as such many of the GenomeQuest searches were not performed
from sequences acquired in this manner.
For this report, the second approach of acquiring sequences from a relevant database proved to
be the main source of sequences used in GenomeQuest searches. The main database used was
the influenza research database.124 Both genetic and protein sequences were acquire from the
database for GenomeQuest searches. The sequences acquired were from influenza viruses that
were found in birds or pigs and additionally with hemagglutinin or Nneuraminidase subtypes of
interest.

124

http://www.fludb.org/brc/influenza_sequence_search_segment_display.do?method=ShowCleanSearch&decorator=i
nfluenza.
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With the sequences found, GenomeQuest searches were used on these sequences. For sequences
acquired from patent documents, the search results, when sorted by the percentage of conformity
to the sequenced searched, the relevant results were patents generally from the same company or
a subsidiary of the company. For sequences from the database, many relevant patents were
found at all levels of conformity. While GenomeQuest did find many relevant patents, these
patents were already identified through keyword searches in either Thomson Innovation or Total
Patent.
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Analysis
Categories of Analysis
Analysis is presented for the two major relevant categories, Vaccines and Supporting
Technologies. The subcategories under each of these major headings were pooled together and
analyzed as a group in order to present a large enough dataset for generating meaningful results.
Parallel analytics were generated for the two major categories, and comparisons are given. The
exceptions were the analysis for multi-jurisdictional filings, which was performed for only
vaccine documents, and the analysis of top assignees, which was performed with both major
groups pooled together. Platform technologies were not analyzed.

ThemeScape Map of Derwent Data
A graphical representation of the results was generated using ThemeScape, a tool within the
Aureka platform initially developed by Aurigin Systems, Inc., and now available through
Innovation.125 ThemeScape creates a virtual “map” of patent data by extracting keywords from
the documents and plotting those topics in relation to one another. “Islands” are formed by
closely related topics and “mountains” are formed when a large number of documents all contain
the same or similar keywords. Gaps between distantly related topics represent an “ocean.”
ThemeScape is a powerful tool which can reveal relationships within a large dataset that are not
otherwise apparent.
ThemeScape provides options for the sources of keywords within each document. The maps
presented below were derived from the DWPI title, DWPI abstract, and claims in English from
one representative of each INPADOC family. Extracting data only from representative
documents prevents large patent families from skewing the results and gives equal weight to
each invention. Not all references had this DWPI data in their records, so the maps represent a
subset of the entire datasets.
The map in Figure 10 shows the topics found with documents coded to the vaccine category.
Many of the topics agree with the coding criteria. At the center right of the map is a mountain
labeled “split influenza” and “pandemic combination,” which would represent subunit vaccines
for a combination of pandemic and seasonal influenza. The bottom center of the map has a
mountain labeled “live, intranasal, embryos” which would indicate live virus vaccines where the
virus is grown in eggs (chicken embryos) and then administered intranasally. Since pandemic
influenza strains cannot be propagated in eggs because the viruses are lethal to the embryos, the
viruses must be attenuated or recombinant (reasserted) so they do not kill the embryos. A peak
125

http://www.intellogist.com/wiki/Report:Thomson_Innovation/Viewing_Results/Analyzing_Results/ThemeScape.
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Figure 10. ThemeScape map of the representative documents from 570 influenza vaccine patent
families.

indicating as much is immediately adjacent to the whole virus vaccine mountain. Other methods
of avoiding this problem of lethality is to express subunits in plants (upper center) or insect cells
(center left). Antigens could also be expressed as polypeptides, possibly in bacteria or
mammalian cells, although these expression systems are not indicated.
The center right and upper right portion of the map has keywords related to the formulation of
vaccines, such as “solution, mixing, adding,” and “oil-in-water emulsion.” Carriers such as
“lipid vesicles” are also represented in the upper center of the map. The center and upper left of
the map represents DNA constructs, or “vectors,” used to generate recombinant viruses or
recombinant subunits. The topics in the upper left such as “plasmid,” “chimeric promoter,” and
“[nucleic] acid molecule encoding,” along with “”delivery device,” most likely indicates DNA
vaccines.
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Figure 11. ThemeScape map of the representative documents from the 750 vaccine supporting
technology families.
The map of the vaccine documents can be contrasted to the map of the supporting technologies
shown in Figure 11. The supporting technologies map contains more “islands,” representing the
broader range of technologies in this category as compared to vaccine documents. The upper left
and upper center sections of the map have keywords related to the subcategory of methods of
making vaccines, such as “harvesting” virus from “eggs” and purifying the virus by “filtration,”
“centrifugation” of the “allontoic fluid” to isolate the virus, and “treating virus-containing fluid”
and then adding “cationic detergent.” Just below those peaks are other methods of preparing
vaccines such as “lyophilization” and “isolated” virus from “serum-free medium.”
The bottom left section of the map is an island which indicates methods of producing virus or
viral subunits, such as “producing negative strand RNA” viruses, “cDNA transcription,” and
“nucleic acid vectors.” Novel viruses useful in vaccines are represented by the “attenuated/cold
adapted” peak in the center of the map. Most of the Russian documents in this subcategory
mentioned use of the viruses to immunize children. The “amino acid/peptide” peak at lower
right would correspond to recombinant subunits, and the “coding/noncoding” peak just beneath
would represent DNA constructs used to produce the recombinant subunits. At extreme lower
left are veterinary vaccines, such as for “equine” influenza. Tetanus toxin is an adjuvant in some
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of these vaccines. “Canarypox virus” is used as a carrier for influenza antigens in some bird
vaccines.
In summary, the two maps are very different which would be expected if the coding of the
documents successfully placed the majority of the documents in the correct subcategories. The
labels on the peaks also correspond to the subcategories. These maps not only reveal the
relationships between the different technologies in each group but they also validate the
document coding protocol which is the basis for the further analytics presented below.

Priority Country v. Document Count
Important questions to ask in the analysis of patent data is “where does the technology come
from?” and “where is the technology being used?” The first question can be answered by
analyzing the priority country, which is the country in which the priority patent document is
filed. Further data can be gleaned from the country in which the top assignees are based, which
is presented below. The second question can be answered by analyzing the multi-jurisdictional
filings, which also follows below.
Although information regarding the priority country is useful, it does not necessarily indicate the
source of the technology. For example, publications HK1154041A0 and HK1156969A0 are
assigned to Medicago, Inc., a Canadian company. However, Medicago126 tends to file
applications first in the U.S., and the priority documents for both of these references are U.S.
applications. Also, IN200503876P1 is assigned to a group of French entities - CNRS, the
Pasteur Institute, and the University of Paris - but the priority document is a Canadian
application. Thus, some assignees file first in other jurisdictions, perhaps to take advantage of
that country’s patent laws or because the patent will be practiced primarily in that country. For
example, Medicago has a manufacturing plant in the U.S., although its research facility is
apparently in Canada.
Most documents have priority data recoded in the Innovation database, but a few do not. In the
majority of cases, priority data can be found through patent family members. When possible,
priority information was added to the data. Such manually corrected data is indicated by
highlighted cells in the files presented in Appendices C and D.
The priority country information for vaccine patent documents is presented in Figure 12. The
United States (US) is by far the largest source of priority documents. China (CN) and Great

126

http://www.medicago.com/.
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Britain (GB) are secondary sources, followed by Russia (RU) and the former Soviet Union (SU),
the European Patent Office (EP), Japan (JP), and Korea (KR).
The priority country information for the supporting technologies documents, shown in Figure 13,
is very similar to that of vaccine documents. All the countries listed above were also the source
of supporting technologies. The major difference is that France (FR) is a more prominent source
of supporting technologies than complete vaccines.

Country

Vaccine Families by Priority Country
AT
AU
BE
CA
CH
CN
CU
DD
DE
DK
EA
EP
FI
FR
GB
HU
IE
IL
IN
IT
JP
KR
MX
NL
PL
RU
SG
SU
TW
UA
US
VN
ZA

Figure 12. The priority country for
each patent family in the vaccine
category (570 total) is indicated.
The countries are represented by the
two-letter codes can be found on the
WIPO website at
http://www.wipo.int/pct/guide/en/gd
vol1/annexes/annexk/ax_k.pdf.
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Supporting Technologies Families by Priority
Country
nd
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CH
CN
DD
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FI
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IE
IN
IT
JP
KR
KZ
MX
NL
RO
RU
SE
SU
TW
UA
US
ZA

Figure 13. The priority country for
each patent family in the
supporting technologies category
(750 total) is indicated. “nd”
means the priority country was not
determined for a few families.
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Top Vaccine Families for Multi-Jurisdictional Filings
Vaccine technologies that have been transferred to the most other countries were calculated by
first determining the size of each INPADOC family within the vaccine document dataset. This
data may be slightly skewed because applications filed in certain jurisdictions are not recorded as
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being members of INPADOC families.127 These jurisdictions include Hong Kong, India,
Mexico, the Philippines, Portugal, Tawain, and Viet Nam. For this reason, the TotalPatent
Extended Family was also retrieved for each of the largest INPADOC families to try to capture
family members from these jurisdictions. It is still possible these jurisdictions remain underrepresented in the dataset. The extended family was not retrieved for all documents because the
export functions of TotalPatent do not allow this data to be captured in a convenient manner.
The number of jurisdictional filings was determined by combining the INPADOC, DWPI, and
TotalPatent families for each representative document.
Twenty-one representative family members had INPADOC families with 29 or more members.
The top family was represented by US20110180430A1, a relatively recent document whose
family already contains 90 members. However, the INPADOC family represented by
US5948410A has been filed in 32 different jurisdictions, which is the most of this group. Four
families are assigned to GlaxoSmithKline and two to Novartis. No other assignee is represented
multiple times. The oldest family is represented by US3953592A, which was filed in 1973.
Three applications published in 2012 are also on the list. These families are shown in Table III,
and the details of each family can be found in Appendix E.
Table III. Top Multi-Jurisdictional Filings per INPADOC Family in the Vaccine Category.
Publication
Number

Size of
INPADOC
Family

Filing Jurisdictions

Total
Number of
Jurisdictions

US20110180430A1 CHIRON SRL |
NOVARTIS

90

19

US20110287054A1 GLAXOSMITHKLINE

76

US20120207786A1 NOVAVAX

69

US20100221284A1 GLAXOSMITHKLINE
| Saech-Sisches
Serumwerk
Dresden

54

AT | AU | BR | CA | CN| DE
| DK | EA | EP | ES | JP | KR
| NZ | PL | PT | SI | US |
WO | IN
AR | AU | BR | CA | CN | EA
| EP | GB | IL | JP | KR| MA
| MX | NO | NZ | PE | SG |
US| WO | ZA| IN | TW
AT | AU | BR | CA | CN | DK
| EP | ES | HK | IL | JP| KR |
MX | NZ | PT | RU | SG | US
| WO | IN | TW
AR | AT | AU | BR | CA | CN
| CO | CZ | DE | DK | EP | ES
| GB | HK | HU | IL | JP| MX
| MY | NO | NZ | PL | PT |
SI | TW | US | WO | ZA | KR
| IN | PH
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Assignee

See also Notes on Patent Families in Appendix M.

67

22

21

31

US8309099B2

St. Jude Children's
Research Hospital

54

US4140762A

SANDOZ SA

53

US7850956B2

Univ.
Massachusetts
Medical Center; St.
Jude Children's
Research Hospital
US20110293650A1 MEDICAGO INC

51

US5948410A

47

DUPHAR
INTERNATIONAL
RESEARCH B.V.

US6716823B1

49

The UAB (Univ. of
Alabama,
Birmingham)
Research
Foundation
US20080038294A1 ABBOTT
BIOLOGICALS BV |
SOLVAY
BIOLOGICALS BV

45

US8119337B2

39

CHIRON BEHRING
GMBH & CO |
NOVARTIS

39

AT | AU | BR | CA | CN | DE
| DK | EA | EP | ES | HK |
HU | IL | JP | KR | MX | NO
| NZ | PL | PT | SI | US |
WO | ZA | IN
AT | AU | BE | CA | CH | CS
| DE | DK | ES | FI | FR | GB
| HK | HU | IE | IL | JP | MY
| NL | NO | PH | PL | SE |
SU | US | YU | ZA | PT
AT | AU | CA | DE | DK | EP
| ES | JP | PT | US | WO

25

AU | CA | CN | CR | EA | EP
| IL | IN | IS | JP | KR | MA |
MX | NZ | RU | US | WO |
VN | HK
US | AR | AT | AU | BR | CA
| CN | CZ | DE | DK | DZ |
EP | ES | GR | HK | HR | HU
| ID | IL | JP | MX | NO | NZ
| PL | PT | RU | SI | SK | TR
| TW | ZA | KR
AT| AU | CA | CN| DE | EP |
ES | HK | JP | KR | MX | US
| WO | ZA | IN

19

AR | AT | AU | BR | CA| CN
| DE | DK | EA | EP | ES |
HR | IL | JP | KR| MX | MY |
NO | PT | SI | TW | US | WO
| ZA | IN | VN
AT | CA | DE | DK | EP | ES |
HK | HR | JP | PT | RS | SI |
US | WO

26

28

11

32

15

14

US20120034264A1 MEDIMMUNE | US
NAT INST OF
HEALTH
US20110129497A1 PEPTIMMUNE INC

36

AU | CA | EP | ES | JP | US |
WO

7

34

AP | AU | CA | CN | EP | IL |
JP | KR | MX | NZ | US | WO

12

US20120219575A1 PEPTCELL LTD

34

AP | AT | AU | BR | CA | CN
| DK | EA | EP | ES | GB | IL
| JP | KR | MX | NO | NZ| PL
| PT | SG | US | WO| ZA |

24

68

IN

US20040087521A1 MERCK & CO INC

33

US6024963A

32

CONNAUGHT LAB
LTD

US7238349B1

GLAXOSMITHKLINE
| Saech-Sisches
Serumwerk
Dresden
US20080260781A1 GLAXOSMITHKLINE

32

US20030124145A1 MERIAL

29

US3953592A

29

Recherche et
Industrie
Therapeutiques
(R.I.T.)

31

US | AU | BG | BR | CA | CN
| CZ | DZ | EP | FI | HR | HU
| IL| JP | NO | NZ | PL | RO
| SG| SI | SK | WO | ZA | ID
| TH
AT | AU | CA | DE | DK | EP
| ES | FI | GR | IL | JP | NO |
PT | US | ZA
AT | AU | BR | CA | DE | DK
| EP | ES | GB | HK | JP | PT
| US | WO

25

AT | AU | CA | DE | EP | ES
| HK | IL | JP | NO | US |
WO
AR | AU | BR | CA | CN | CO
| DE | EP | ES | FR | HU | ID
| JP | MA | NZ | US | WO |
MX | KR | IN
US | AT | AU | BE | CA | CH
| CS | DE | DK | ES | FI | FR
| GB | HU | IE | IL | JP | LU
| NL | NO | SE| ZA | PT

12

15

14

20

23

Global Filing Trends for Influenza A Virus Vaccines
The previous section assessed filing trends for individual family trends. The entire vaccine
category was analyzed to determine the jurisdictions in which the entire vaccine population were
filed. The INPADOC and DWPI patent families were combined for each reference document,
and each jurisdiction was counted only once per family. For example, if a representative
document had three European Patent Office applications, the EPO was counted once for that
family. The TotalPatent families were not incorporated into this dataset, due to the difficulties
with exporting such data. Thus, certain jurisdictions such as India, Taiwan and the Philippines
may be under-represented.
Of over 230 possible different jurisdictions in which patent applications could potentially be
filed, influenza vaccine families were filed in a total of 68 jurisdictions. As shown in Figure 14,
North America and Europe are popular locations for assignees to seek protection for influenza
vaccine inventions. Of Asian countries, China, India, Japan, South Korea (i.e. the Republic of
Korea), Vietnam, Singapore, and Hong Kong were targets for filing. Most families were also
filed Australia and New Zealand. However, Central and South America, other than Brazil, were
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Jurisdiction

Patent Family
Filings by
Jurisdiction

Algeria
Argentina
ARIPO
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
Chile
China
Colombia
Cooperation Council for Arab States of Gulf
Costa Rica
Croatia
Cuba
Czech Republic
Czechoslovakia
Denmark
Ecuador
Eurasian Patent Organization (EAPO)
European Patent Office (EPO)
Finland
France
Germany
Greece
Hong Kong Special
Hungary
Iceland
India
Indonesia
Ireland
Israel
Italy
Japan
Luxembourg
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Nicaragua
Norway
Peru
Philippines
Poland
Portugal
Romania
Russian Federation
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Soviet Union
Spain
Sweden
Switzerland
Taiwan
Turkey
Ukraine
United Kingdom
United States of America
Viet Nam
West Germany
WIPO
Yugoslavia/Serbia and Montenegro

Figure 14. Distribution of
jurisdictional filings by vaccine
patent families. This data is also
plotted in Figure 15.
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Figure 15. Global filing trends by country. The number of patent families that have sought
protection in a given country are indicated by colors. Countries shown in white have no
identified filings among the 570 influenza vaccine patent families. Multijurisdictional agencies,
such as WIPO and the EPO, are not indicated.

poorly represented, and no filings were done in any African country other than South Africa.
Countries are only shown in Figure 14 if at least one filing occurred in that country.
The jurisdictions where each patent family chose to seek patent protect was also plotted on a
world map (see Fig. 15, above). Each jurisdiction is indicated once per family. For example, if a
given patent family filed three U.S. applications, the United States was counted once for that
family. Greenland was considered part of Denmark for this analysis. Also, the former
Yugoslavia was indicated under Serbia and Montenegro, the former Czechoslovakia under the
Czech Republic, and the former Soviet Union under Russia. Multijurisdictional agencies were
not plotted. Nearly 70% of patent families had filed PCT applications with WIPO, so excluding
PCT filings probably did not skew the results, as each country was affected equally. Also, since
the map only indicates countries where PCT applications entered the national phase, the map
gives a more accurate portrayal of the jurisdictions in which assignees are most interested.
However, exclusion of filings at the European Patent Office (EPO), probably does leave some
European countries slightly underrepresented on the map. Other multijurisdictional agencies not
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indicated on the map are the Eurasian Patent Office (EAPO)128 which consists of countries
belonging to the former Soviet Union and in which 20 patent families filed, the African Regional
Intellectual Property Organization (ARIPO)129 which currently represents 18 nations and in
which seven patent families filed, and the Cooperation Council for the Arab States of the Gulf
(GCC)130 which represents six nations on the Arabian peninsula and in which two patent families
filed. Due to the time-consuming nature of this analysis, only influenza vaccines patent families
were analyzed and plotted as above.
The map demonstrates that the majority of patent families file in just a few countries. The top
nations for filings, indicated in red, are Australia, Canada, China, Japan, the Republic of Korea
(South Korea), and the United States. Secondary target nations, indicated in purple, are Brazil,
Germany, India, Mexico, and New Zealand, followed by a group (in blue) that includes Austria,
Norway, Russia, Spain, and South Africa. A final group (in green) includes the Philippines,
Vietnam, and several European nations. No other nation had more than 20 patent family filings.
Filings were particularly sparse in South America and Africa.

Top Assignees by Patent Document Count
Assignee data for patent documents is often inaccurate. The patent rights could be sold to
another assignee, who does not record the assignee. Also, a company holding the rights changes
its name or is sold in toto and new assignments are not recorded. Some companies do not record
an assignment until a patent is allowed, so published applications that are later abandoned or
rejected do not have assignment data. Outside of the U.S., university faculty members retain
rights in their inventions so the name of the university is not given on the patent document.
None of the patent databases maintain accurate updates for such changes or account for such
missing data.
Correction of patent assignee information must be performed manually. While this represents a
burden on clinic members’ time, such information would is invaluable to the use of the clinic
report. Accurate assignee information is essential in order for the report data to be updated, and
so the correct owners of the technologies can be contacted for licensing inquiries.
The main protocol for correcting assignee names is to use Google, searching for the company
website or new releases about the company. Business Week131 is a great source of information,
as are technology-specific business reporters such as Fierce Biotech132. These sources reveal the

128

http://www.eapo.org/en/.
http://www.aripo.org/.
130
http://www.gcc-sg.org/eng/.
131
http://www.businessweek.com/.
132
http://www.fiercebiotech.com/.
129
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current accurate name of the company listed as the assignee or whether the company is now a
wholly-owned subsidiary of a larger company.
If no information was readily obtainable, the assignee was searched using Innovation, restricting
the date field to after the publishing date of the known document. The Derwent Assignee field
may have another assignee commonly listed with the company being researched. A Google
search of the two names together sometimes revealed a link between the two, such as a name
change or an acquisition. The Derwent assignee code133 is another source of assignee
information. Other companies may be linked to the same code, such as ASTR being used for
both AstraZeneca and its acquired company MedImmune.
If the only information available is the inventor name(s), then the document was located on
Google Patent134. This website has hyperlinks to other patent documents by the same inventor
which may have assignee data recorded. The name of the inventor was also searched on Google
to find an association between the inventor and a particular company. To make the search more
accurate, the search includes both the inventor’s name and some keywords from the patent
document. LinkedIn135 and other networking websites are another source of information, and
can be especially useful if an inventor is associated with multiple companies. Typically the date
of the application can be associated with a date range for when the inventor was working for one
company rather than another. Since patent applications can be filed months if not years after the
date of the invention, this latter method was used with caution.
Using the above methodology, the assignee information for each relevant document in the
vaccine and supporting technologies categories was manually corrected as accurately as possible.
The results were then sorted on assignee names to reveal the number of patent families
associated with each assignee. The two categories were analyzed together so a single list of
assignees was generated, which is presented in Table IV.
Twenty-one assignees had seven or more patent families each. While the top four assignees –
Novartis, GSK, Pfizer, and U.S. Merck - are for-profit companies, half of the assignees (12) are
government agencies or non-profit institutions. More assignees (7) are based in the United
States than any other country. Three institutions are located in China, and two each are based in
Great Britain, Japan, Korea, and Russia. Switzerland, Germany, and France have one assignee
each.

133

http://ip-science.thomsonreuters.com/support/patents/dwpiref/reftools/companycodes/lookup/.
www.google.com/patents.
135
http://www.linkedin.com.
134
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Table IV. Assignees with the Most INPADOC Patent Families in the Vaccines and Supporting
Technologies Categories Combined (1,320 Families).
Standardized Assignee

Number of
Families

Home
Country

Novartis
GlaxoSmithKline
Pfizer
Merck and Co. (Merck Sharpe & Dohme)
Nauchno-issledovatel'skij institut ehksperimental'noj meditsiny
RAMN (Scientific Research Institute of Experimental Medicine,
RAMS)

33
25
25
23
23

CH
GB
US
US
RU

Sanofi
AstraZeneca
University of Wisconsin
US Department of Health
Baxter International
Saint Jude's Hospital
Chinese Academy of Agricultural Sciences
Chinese Academy of Sciences
Kaketsuken
Institute of Medical Biology Chinese Academy of Medical
Sciences

21
20
18
16
15
15
14
11
9
8

FR
GB
US
US
US
US
CN
CN
JP
CN

Ministry for Food Agriculture, Forestry and Fisheries (Korea)
Mount Sinai Hospital
Boehringer Ingelheim
Choong and Vaccine Laboratory
Ministry of Health, Labour and Welfare (Japan)
Vsesoyuznyj Nauchno-Issledovatelskij Institut Grippa (Union
Scientific Research Institute of Influenza)

8
8
7
7
7
7

KR
US
DE
KR
JP
RU

Top Inventors by Patent Document Count
Of all patent data, inventor names are probably the most error-prone. Inventor names do not
change as assignee names tend to do, but inventor names are listed in a number of different
ways. The inventor name may include a middle initial or not, or the middle name may be spelled
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out entirely.136 Names may be misspelled.137 Last names may be hyphenated or the hyphen may
be absent.138 First and last names may even be switched.139
Because of these errors, analysis of inventors using the databases is extremely inaccurate, as
those calculations treat each variant of a name as a different inventor. Thus, inventor names
were reviewed manually and corrections made when possible. The DWPI Inventor field lists
alternative versions of inventors’ names, although sometimes more research is needed to
determine which one of those variants is the correct name. The most accurate source of inventor
names is the scientific literature, which, unlike patents, is carefully edited prior to publication.
Table V lists 30 inventors who each was an inventor of four or more patent families with the
vaccines category. The assignees associated the inventors are also given. Curiously, this list of
top inventors does not match the top assignee data, as only one Novartis inventor appears on the
list and no GSK inventors are present. The top five inventors are all Russian. Complete inventor
data for the vaccine category are given in Appendix H.

Table V. Top Inventors of Vaccine Patent Families.
Standarized Inventor Name

Number of
Documents

Assignee - DWPI

Aleksandrova, Galina
Ibragimovna

27

A MED EXPER MED RES INST

Rudenko, Larisa Georgievna
Klimov, Aleksandr I
Kiseleva, Irina Vasil Evna
Romanova, Julia

24
16
15
8

A MED EXPER MED RES INST
A MED EXPER MED RES INST
A MED EXPER MED RES INST
A MED EXPER MED RES INST| AVIR GREEN HILLS
BIOTECHNOLOGY TRADE AG | POLYMUN SCI
IMMUNBIOLOGISCHE FORSCHUNG

Egorov, Andrej

7

POLYMUN SCI IMMUNBIOLOGISCHE FORSCHUNG | AVIR
GREEN HILLS BIOTECHNOLOGY RES AG

Barrett, P. Noel
Kistner, Otfried
Webster, Robert G.
Arnon, Ruth
Kawaoka, Yoshihiro

6
6
6
5
5

BAXTER HEALTHCARE SA
BAXTER HEALTHCARE SA
WYETH | ST JUDE CHILDREN'S RES HOSPITAL
YEDA RES & DEV CO LTD
WISCONSIN ALUMNI RES FOUND

136

An example from the vaccine inventor list is Galina Ibragimovna Aleksandrova, who is also listed as Galina I.
Aleksandrova and G. I. Aleksandrova.
137
RU2319744C2 misspells Aleksandrova’s middle name by dropping the “A” at the end.
138
For example, Derwent information shows at least five different versions of Wilson Romero CapparrosWanderley’s name. See US20120219575A1.
139
Compare Robert G. Webster’s name on US8293247B2 and CA813864A.
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O'Hagan, Derek

5

CHIRON CORP | NOVARTIS VACCINES&DIAGNOSTICS INC

Polezhaev, Fial I

5

EXPER MEDICAL RES | KALIN SANITARY EPIDEMY | VIRUS
MEDICAMENTS RES

Sambhara, Suryaprakash

5

AVENTIS PASTEUR LTD | CONNAUGHT LAB LTD | PURDUE RES
FOUND

Seong, Baik Lin
Ben-Yedidia, Tamar
Chatfield, Steven Neville

5
4
4

BIOTRION CO LTD | PROTHEON CO LTD
YEDA RES & DEV CO LTD | BIONDVAX PHARM LTD
ARCHIMEDES DEV LTD | DANBIOSYST UK LTD | MEDEVA
HOLDINGS BV | WEST PHARM SERVICES DRUG DELIVERY &
CLIN

Dorner, Friedrich
Ferko, Boris

4
4

BAXTER HEALTHCARE SA
POLYMUN SCI IMMUNBIOLOGISCHE FORSCHUNG | AVIR
GREEN HILLS BIOTECHNOLOGY RES AG

Galarza, Jose M.

4

AMERICAN CYANAMID CO | WYETH HOLDINGS CORP |
TECHNOVAX INC

Kemble, George
Larionova, Natalja
Valentinovna

4
4

MEDIMMUNE INC
AS SIBE MED EXPERIMENTAL MED RES INST

Medvedeva, Tamilla E

4

AMS EXP MED RES INS | INFLUENZA RES INST | MED BIOLK
PREP STANDARD | MOSC VIRUS PREPD RES INST

Nabel, Gary J.
Ohkuma, Kunio

4
4

US DEPT HEALTH&HUMAN SERVICES
CHEMO SERO THERAPEUTIC RES INS |NAT INST OF HEALTH
JAPAN

Osterhaus, Albert D.M.E.

4

ABBOTT BIOLOGICALS BV | SOLVAY BIOLOGICALS BV | UNIV
ROTTERDAM ERASMUS CENT MEDICAL

Wei, Chih-Jen
Wolschek, Markus
Yang, Chin-Fen
Yang, Zhi-Yong

4
4
4
4

US DEPT HEALTH&HUMAN SERVICES
AVIR GREEN HILLS BIOTECHNOLOGY RES AG
MEDIMMUNE INC
US DEPT HEALTH&HUMAN SERVICES

The same analysis was performed with supporting technologies documents, as shown in Table
VI. There were more inventors (47) with four or more patent families, but number of patent
documents per inventor was lower than that with the vaccine documents. For example, G.I.
Aleksandrova was the top inventor on both lists, but this inventor had 27 patents documents in
the vaccines category but only 15 in the supporting technologies category. Overall, this agrees
with the previous determination that the supporting technologies category represents a more
diverse pool of documents than the documents in the vaccines category. Many of the vaccine
inventors also appear on the supporting technologies list, which was probably to be expected.
The assignees associated with these inventors are surprisingly different from the vaccine
inventors list. GSK is represented on the supporting technologies list of inventors but Pfizer and
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Merck are not. Non-profit entities are more represented, with 34 of the 47 inventors working for
such institutions. Russian and Chinese inventors were prominent on the top of the supporting
technologies inventor list. A prominent person on this list is Dr. Peter Palese,140 of Mount Sinai
School of Medicine in New York, USA. Dr. Palese uses reverse genetics as a tool to modify and
study pandemic influenza strains.141
Complete inventor data for the supporting technologies category are given in Appendix I.

Table VI. Top Inventors of Supporting Technologies Patent Families.
Standardized Inventor
Name

Number of
Documents

Assignee - DWPI

Aleksandrova, Galina
Ibragimovna

15

A MED EXPER MED RES INST

Kawaoka, Yoshihiro

15

ST JUDE CHILDREN'S RES HOSPITAL | US DEPT
HEALTH & HUMAN SERVICES

Rudenko, Larisa
Georgievna

14

A MED EXPER MED RES INST

Klimov, Aleksandr I
Chen, Hua-lan

11
10

A MED EXPER MED RES INST
CHINESE ACAD AGRIC SCI HARBIN VETERINARY
MEDICINE INST

Smith, Gail Eugene

9

MG-PMC LLC | MICROGENESYS INC | PROTEIN SCI
CORP

Bu, Zhi-gao

8

CHINESE ACAD AGRIC SCI HARBIN VETERINARY
MEDICINE INST

Gendon, Yury
Zakharovich

8

NIZHEGOROD EPIDEMICS MICROBIOLOG INST |
VEKTOR VIROLOGY & BIOTECH RES CENTRE

Palese, Peter M.
Webster, Robert G.
Garcia-Sastre, Adolfo

8
8
7

MOUNT SINAI SCHOOL MEDICINE
ST JUDE CHILDREN'S RES HOSPITAL
ISIS INNOVATION LTD | UNIV NEW YORK MT SINAI
SCHOOL MEDICINE

Polezhaev, Fial I
Yoon, In Joong
LI, Ying-bo
Seo, Sang Heui
Chen, Qin-qin
LI, Hui
Neumann, Gabriele
Shin, Yeun-Kyung

7
7
6
6
5
5
5
5

140
141

CHOONG ANG VACCINE LAB | VACCINE LEADER
CHINESE ACAD SCI KUNMING INST ZOOLOGY
CHOONG ANG VACCINE LAB | VACCINE LEADER
CHINESE ACAD SCI KUNMING INST ZOOLOGY
WISCONSIN ALUMNI RES FOUND
REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI

See e.g. http://www.mountsinai.org/profiles/peter-palese.
See e.g. http://www.sciencemag.org/content/310/5745/77.short.
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Song, Jae Young

5

REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI |
UNIV CHUNGBUK NAT IND ACAD COOP FOUND

Akopova, Irina Ivanovna

4

NIZHEGOROD EPIDEMICS MICROBIOLOG INST |
VEKTOR VIROLOGY & BIOTECH RES CENTRE

Andre, Bruno, Rene
Audonnet, JeanChristophe Francis

4
4

GLAXOSMITHKLINE
MERIAL | MERIAL SAS | RHONE MERIEUX SA

Cao, Yong-chang
Champluvier, Benoit Paul
Suzanne

4
4

UNIV SUN YET-SEN
GLAXOSMITHKLINE

Choi, Young Ki

4

REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI |
UNIV CHUNGBUK NAT IND ACAD COOP FOUND

Couture, Manon
Egorov, Andrej
Garmashova, Lyudmila M
Gou, Hong-ying

4
4
4
4

MEDICAGO INC
A MED EXPER MED RES INST

Jiang, Yong-ping
Jin, Hong
Kim, Hyun Soo
Kwon, Hyuk Il

4
4
4
4

HARBIN VETERINARY RES INST CAAS
MEDIMMUNE LLC | MEDIMMUNE VACCINES INC
CHOONG ANG VACCINE LAB | VACCINE LEADER
REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI |
UNIV CHUNGBUK NAT IND ACAD COOP FOUND

Larionova, Natalja
Valentinovna

4

A MED EXPER MEDICINE RES INST

Liu, Da-cai
Markushin, Stanislav
Georgievich

4
4

UNIV SUN YET-SEN
NIZHEGOROD EPIDEMICS MICROBIOLOG INST |
VEKTOR VIROLOGY & BIOTECH RES CENTRE

Medvedeva, Tamilla E
Murphy, Brian R.
O'Hagan, Derek

4
4
4

Pushko, Peter M.
Song, Min Suk

4
4

NOVAVAX INC
REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI |
UNIV CHUNGBUK NAT IND ACAD COOP FOUND

Vezina, Louis-Philippe
Wang, Cheng-yu

4
4

MEDICAGO INC
LIAONING TIANCHENG INST BIOLOGICAL MEDIC |
TIANCHENG INST BIOLOGICAL PHARMACY LIAON

Xue, Chun-yi
Yoon, So Ra

4
4

UNIV SUN YET-SEN
REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI |
UNIV CHUNGBUK NAT IND ACAD COOP FOUND

Yoon, Soon Seek

4

REPUBLIC KOREA MANAGEMENT MIN AGRIC&FI |
UNIV CHUNGBUK NAT IND ACAD COOP FOUND

LIAONING TIANCHENG INST BIOLOGICAL MEDIC |
TIANCHENG INST BIOLOGICAL PHARMACY LIAON

ST JUDE CHILDREN'S RES HOSPITAL
CHIRON CORP | NOVARTIS VACCINES &
DIAGNOSTICS INC
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Publication Year v. Patent Document Count
Trends in publication of patent documents were analyzed for the two major categories.
Publication date was chosen as the parameter for analysis, which indicates publication of
applications generally 18 months after filing and publication of patents after allowance. In the
few cases in which the publication date was not recorded, the year of publication could usually
be found in DWPI data such as the DWPI update information.

Vaccine Patent Publications by Year
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Figure 16. Publication trends for patent families in the influenza vaccine category. The year of
publication of each representative document of the 570 families is shown.
The earliest representative family member in the vaccine category was a U.S. patent issued in
1948, as shown in Figure 15. The second place document was published 16 years later in 1964.
From the mid 1960s until the mid 1990s, only one or two patents were published, on average. In
1997, the average number of publications leapt to 10, possibly because the TRIPS Agreement
took effect in 1996 and patent applications began to be published 18 months after filing. In
2006, the number of influenza vaccine-related publications began to steadily climb, up to 104 in
2011. The number of publications in 2012 was approximately equal to that peak, especially
considering this report includes a thorough search of patent only up to early October 2012, and
thus the search did not cover the entire calendar year.
The increase in filing of patent applications also correlates with the H5N1 (bird flu) epidemic
that began in 1997, and was probably driven even higher following the 2009 H1N1 (swine flu)
pandemic.
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The data may be somewhat skewed because the representative family member was chosen as the
latest publication from the U.S., or the latest document from another jurisdiction if there was no
U.S. family member. However, the trend still indicates an increased interest in influenza vaccine
technologies in the last case.
Supporting technology publication trends present a similar story, as shown in Figure 16. Only
three such documents were published before 1966. In the 1970s, there was a higher average
level of patent publication than that for vaccine patents, but this average dropped to only two
documents per year in the late 1980s and early 1990s. There was a small increase when
applications began to be published. However, since at least 2004 there has been a steady
increase in publication of supporting technology documents. In fact, even though the data is not
complete 2012, there were still 151 publications in that partial year, which represents a
substantial increase over the 102 publications in 2011. Again, this increase in patent filings is
likely driven by a response to the 1997 H5N1 epidemic and the 2009 H1N1 pandemic.
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Figure 17. Publication trends for patent families in the supporting technologies category. The
year of publication of each representative document of the 750 families is shown.
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U.S. Classification by Patent Document Count
Every patent application submitted to the U.S.P.T.O. receives a preliminary classification which
determines the art unit in which that application is examined. The patent examiner assigns other
classes to the application as she feels appropriate to indicate the technologies important the
particular invention disclosed by the application. The U.S. Patent Classification System (USPC)
“ is a system for organizing all U.S. patent documents and many other technical documents into
relatively small collections based on common subject matter.”142 The USPC groups similar
patent documents together into small classes which can be searched. For example, once a
relevant document is identified, an interested person could search the U.S. class of that document
for other relevant references. This represents an alternative to keyword searching for relevant
documents, and this system may help identify relevant documents when specific keywords are
difficult to ascertain. Certainly, class searching should supplement any keyword search to ensure
all relevant documents are identified.
The U.S.P.T.O. is currently revising its classification system to bring the USPC into harmony
with the European Classification System (ECLA) to facilitate identification of relevant
documents from multiple jurisdictions.143 While the USPC is being revised, it is useful to
present an analysis of the current USPC since complete harmonization has not been achieved to
date.
Figure 17 shows the 53 different classes that have been assigned to influenza vaccine documents
by the U.S.P.T.O. Most documents were assigned to Class 424, particularly the subclasses
209.1, 210.1, 206.1, and 186.1. The definitions for each of the top classes are given in Table
VII. Class 424 is related to vaccines, and subclasses 209.1, 206.1, and 210.1 are specifically
limited to influenza vaccines. Class 424/450 is directed to liposomes as carriers in vaccines.
Classes 514/044R and 435/320.1 are directed to DNA sequences, probably as used in DNA
vaccines or in the production of recombinant viruses and subunits.
As indicated before, the supporting technologies category contains a broader range of inventions
so there are 74 different classes assigned to documents in this category, as shown in Figure 18.
Many of the top classes are the same between the two categories, including the number one class
on both lists, 424/209.1. The list of top classes for supporting technologies did have three
classes that were not prominent with vaccine documents. Class 435/239 contains technologies
related to virus purification, which would describe the subcategory of methods of making
vaccines. Additionally, Classes 435/069.3 and 435/069.1 contains recombinant peptides, which
could include novel subunits useful in vaccines. Table VIII lists the definitions of these classes.

142
143

http://www.uspto.gov/patents/resources/classification/overview.pdf.
http://www.uspto.gov/patents/resources/classification/index.jsp.
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Main U.S. Class

Vaccines: Main U.S. Class per INPADOC Family
206/223
424/009.2
424/085.1
424/085.6
424/093.1
424/093.2
424/093.6
424/130.1
424/133.1
424/147.1
424/159.1
424/185.1
424/186.1
424/189.1
424/192.1
424/193.1
424/194.1
424/196.11
424/199.1
424/200.1
424/201.1
424/202.1
424/203.1
424/204.1
424/205.1
424/206.1
424/209.1
424/210.1
424/226.1
424/227.1
424/278.1
424/283.1
424/400
424/450
424/490
424/491
424/499
424/526
435/005
435/069.3
435/091.1
435/091.4
435/173.3
435/235.1
435/320.1
514/044R
530/328
530/350
536/023.1
536/024.1
800/298

Figure 18. USPC classes assigned
to influenza vaccine documents.
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Table VII. Top U.S. Classes for Vaccine Documents.
US Class Main

# Docs

Class Title

424/209.1

45

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELLDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):
Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.)

424/206.1

32

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELLDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):
Reassortant or deletion mutant virus (205.1): Influenza virus

424/186.1

23

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELLDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Amino acid sequence disclosed in whole
or in part; or conjugate, complex, or fusion protein or fusion polypeptide
including the same (185.1): Disclosed amino acid sequence derived from
virus

424/210.1

18

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELLDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):
Orthomyxoviridae (209.1): Subunit vaccine containing hemagglutinin or
neuraminidase

424/450

10

PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM (400):
Liposomes

424/199.1

9

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELLDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Recombinant virus encoding one or
more heterologous proteins or fragments thereof

424/192.1

7

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELLDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Fusion protein or fusion polypeptide
(i.e., expression product of gene fusion)

83

424/202.1

6

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELLDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Combination of antigens from multiple
viral species (e.g., multivalent viral vaccine, etc.)

514/044R

6

DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI) (001):
Carbohydrate (i.e., saccharide radical containing) DOAI (023): N-glycoside
(042): Nitrogen containing hetero ring (043): Polynucleotide (e.g., RNA, DNA,
etc.)

424/204.1

5

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELLDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof

435/235.1

5

VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE
VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION
THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING

435/005

4

MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF
FORMING SUCH COMPOSITION OR TEST STRIP (004): Involving virus or
bacteriophage

424/185.1

4

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELLDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Amino acid sequence disclosed in whole
or in part; or conjugate, complex, or fusion protein or fusion polypeptide
including the same

435/320.1

4

VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR,
BACTERIOPHAGE VECTOR, ETC.)

84

U.S. Class

Supporting Technologies - Main U.S. Class
206/223
30h/0006
424/085.4
424/093.2
424/093.3
424/0934.5
424/130.1
424/159.1
424/169.1
424/184.1
424/186.1
424/189.1
424/192.1
424/193.1
424/194.1
424/199.1
424/200.1
424/201.1
424/202.1
424/204.1
424/206.1
424/207.1
424/208.1
424/209.1
424/210.1
424/214.1
424/229.1
424/234.1
424/239.1
424/400
424/450
424/463
424/484
424/489
424/729
435/005
435/006.16
435/007.92
435/041
435/069.1
435/069.3
435/091.1
435/173.3
435/173.9
435/188
435/201
435/235.1
435/236
435/237
435/238
435/239
435/252.3
435/252.33
435/254.11
435/260
435/272
435/320.1
435/440
435/455
435/456
435/471
514/044A
514/044R
530/345
530/350
530/387.1
530/412
536/023.1
536/023.72
705/002
800/008
800/019
800/288
800/298

Figure 19. USPC classes assigned
to supporting technologies
documents.
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Table VIII. Top U.S. Classes for Supporting Technology Documents.
US Class Main

# Docs

Class Title

424/209.1

50

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):
Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.)

424/210.1

15

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):
Orthomyxoviridae (209.1): Subunit vaccine containing hemagglutinin or
neuraminidase

435/239

14

VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE
VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION
THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING
(235.1): Recovery or purification

424/199.1

13

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Recombinant virus encoding one or
more heterologous proteins or fragments thereof

424/206.1

12

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof (204.1):
Reassortant or deletion mutant virus (205.1): Influenza virus

424/204.1

11

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Virus or component thereof

435/235.1

9

VIRUS OR BACTERIOPHAGE, EXCEPT FOR VIRAL VECTOR OR BACTERIOPHAGE
VECTOR; COMPOSITION THEREOF; PREPARATION OR PURIFICATION
THEREOF; PRODUCTION OF VIRAL SUBUNITS; MEDIA FOR PROPAGATING

86

424/186.1

9

ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G.,
IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-DIATED
IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC
IMMUNOSUPPRESSOR, ETC. (184.1): Amino acid sequence disclosed in whole
or in part; or conjugate, complex, or fusion protein or fusion polypeptide
including the same (185.1): Disclosed amino acid sequence derived from virus

435/005

7

MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF
FORMING SUCH COMPOSITION OR TEST STRIP (004): Involving virus or
bacteriophage

435/069.3

4

435/069.1

4

424/450

4

MICROORGANISM, TISSUE CELL CULTURE, OR ENZYME USING PROCESS TO
SYNTHESIZE A DESIRED CHEMICAL COMPOUND OR COMPOSITION (41):
Recombinant DNA technique included in method of making a protein or
polypeptide (69.1): Antigens
MICROORGANISM, TISSUE CELL CULTURE, OR ENZYME USING PROCESS TO
SYNTHESIZE A DESIRED CHEMICAL COMPOUND OR COMPOSITION (41):
Recombinant DNA technique included in method of making a protein or
polypeptide
Recombinant DNA technique included in method of making a protein or
polypeptide

Top IPC (Current) Classifications
The International Patent Classification (IPC) system, established in 1971, is administrated by the
World Intellectual Property Organization (WIPO). The IPC “provides for a hierarchical system
of language independent symbols for the classification of patents and utility models according to
the different areas of technology to which they pertain.”144 The IPC contains eight core sections
with approximately 70,000 subdivisions, called advanced levels. WIPO continuously revises the
IPC, with the core levels being updated every three years and the advance levels being reviewed
a few times each year. The current version of the core levels was released in 2012.
The IPC (Current) codes were analyzed for each patent family. Some families had more than
one code, and each was counted. For the vaccine category, 15 codes represented more than 20
families each, as shown in Figure 19. The two classes that represented the most families were
A61K 39/145, which contains preparations of influenza antigens such as a vaccine, and A61P
31/16, which contains pharmaceutical compositions used to treat influenza infections. The
definitions of the top IPC classes for vaccine documents are given in Table IX.
144

World Intellectual Property Organization, Preface to the International Patent Classification (IPC), WIPO IP
SERVICES, http://www.wipo.int/classifications/ipc/en/general/preface.html (last visited Apr. 18, 2012).
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Figure 20. Top IPC (Current) Classification of Vaccine Families. Each class represented at least
21 different families.
Table IX. Definitions of the Top IPC (Current) Classifications of Vaccine Documents.
IPC - Current
A61K 39/00

# Docs
55

Class Description
MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations
containing antigens or antibodies

A61K 39/12

34

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations
containing antigens or antibodies (A61K 39/00): Viral antigens

A61K 39/145

297

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations
containing antigens or antibodies (A61K 39/00): Viral antigens (39/12):
Orthomyxoviridae, e.g. influenza virus

A61K 39/295

25

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations
containing antigens or antibodies (A61K 39/00): Viral antigens (39/12):
Polyvalent viral antigens; Mixtures of viral and bacterial antigens

A61K 39/39

47

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations
containing antigens or antibodies (A61K 39/00): characterised by the
immunostimulating additives, e.g. chemical adjuvants

88

A61K 48/00

29

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal preparations
containing genetic material which is inserted into cells of the living body to
treat genetic diseases; Gene therapy

A61P 31/12

22

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives, i.e.
antibiotics, antiseptics, chemotherapeutics (A61P 31/00): Antivirals

A61P 31/16

158

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives, i.e.
antibiotics, antiseptics, chemotherapeutics (A61P 31/00): Antivirals (31/12):
for RNA viruses (31/14): for influenza or rhinoviruses

A61P 37/04

59

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Drugs for immunological
or allergic disorders (A61P 37/00): Immunomodulators (37/02):
Immunostimulants

C07K 14/11

68

ORGANIC CHEMISTRY (C07): Peptides having more than 20 amino acids;
Gastrins; Somatostatins; Melanotropins; Derivatives thereof (C07K 14/00):
from viruses (14/005): RNA viruses (14/08): Orthomyxoviridae, e.g. influenza
virus

C12N 07/00

59

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Viruses, e.g.
bacteriophages; Compositions thereof; Preparation or purification thereof

C12N 07/01

34

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Viruses, e.g.
bacteriophages; Compositions thereof; Preparation or purification thereof
(C12N 07/00): Viruses, e.g. bacteriophages, modified by introduction of
foreign genetic material

C12N 07/04

30

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Viruses, e.g.
bacteriophages; Compositions thereof; Preparation or purification thereof
(C12N 07/00): Inactivation or attenuation; Producing viral sub-units

C12N 15/44

25

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Mutation or
genetic engineering; DNA or RNA concerning genetic engineering, vectors,
e.g. plasmids, or their isolation, preparation or purification; Use of hosts
therefor (C12N 15/00): Recombinant DNA-technology (15/09): DNA or RNA
fragments; Modified forms thereof (15/11): Genes encoding microbial
proteins, e.g. enterotoxins (15/31): Genes encoding viral proteins (15/33):
Proteins from RNA viruses, e.g. flaviviruses (15/40): Orthomyxoviridae, e.g.
influenza virus

89

C12N 15/63

21

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12): Mutation or
genetic engineering; DNA or RNA concerning genetic engineering, vectors,
e.g. plasmids, or their isolation, preparation or purification; Use of hosts
therefor (C12N 15/00): Recombinant DNA-technology (15/09): Introduction
of foreign genetic material using vectors; Vectors; Use of hosts therefor;
Regulation of expression

Again, the supporting technologies category had a broader spectrum of top classes, with 20
different classes each representing at least 21 families, as shown in Figure 20. However, the top
two classes, A61k 39/145 and A61P 31/16, were the same as with the vaccine category. Two of
the five additional classifications, C12N 15/09 and A61P 31/14 were merely higher level
classifications of previously identified, more narrow classes. The three new classes were C12N
05/10, which concerns culture of transformed cell lines such as for the production of viruses or
viral subunits, C12N 07/02, which concerns methods of purifying viruses, and C12N 15/86,
which concerns DNA constructs such as for producing recombinant polypeptides. Complete
definitions are located in Table X.
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Figure 21. Top IPC (Current) Classification of Supporting Technology Documents. Each class
represented at least 21 different families.
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Table X. Definitions of the Top IPC (Current) Classifications of Supporting Technology
Documents.
IPC - Current
A61K 39/00

# Docs
69

Class Definitions
MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal
preparations containing antigens or antibodies

A61K 39/12

85

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal
preparations containing antigens or antibodies (A61K 39/00): Viral
antigens

A61K 39/145

362

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal
preparations containing antigens or antibodies (A61K 39/00): Viral
antigens (39/12): Orthomyxoviridae, e.g. influenza virus

A61K 39/295

37

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal
preparations containing antigens or antibodies (A61K 39/00): Viral
antigens (39/12): Polyvalent viral antigens; Mixtures of viral and
bacterial antigens

A61K 39/39

26

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal
preparations containing antigens or antibodies (A61K 39/00):
characterised by the immunostimulating additives, e.g. chemical
adjuvants

A61K 48/00

29

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Medicinal
preparations containing genetic material which is inserted into
cells of the living body to treat genetic diseases; Gene therapy

A61P 31/12

41

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives,
i.e. antibiotics, antiseptics, chemotherapeutics (A61P 31/00):
Antivirals

A61P 31/14

22

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives,
i.e. antibiotics, antiseptics, chemotherapeutics (A61P 31/00):
Antivirals (31/12): for RNA viruses

A61P 31/16

169

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Antiinfectives,
i.e. antibiotics, antiseptics, chemotherapeutics (A61P 31/00):
Antivirals (31/12): for RNA viruses (31/14): for influenza or
rhinoviruses

A61P 37/04

48

MEDICAL OR VETERINARY SCIENCE; HYGIENE (A61): Drugs for
immunological or allergic disorders (A61P 37/00):
Immunomodulators (37/02): Immunostimulants

C07K 14/11

87

ORGANIC CHEMISTRY (C07): Peptides having more than 20 amino
acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
(C07K 14/00): from viruses (14/005): RNA viruses (14/08):
Orthomyxoviridae, e.g. influenza virus

91

C12N 05/10

33

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12):
Undifferentiated human, animal or plant cells, e.g. cell lines;
Tissues; Cultivation or maintenance thereof; Culture media
therefor (C12N 5/00): Cells modified by introduction of foreign
genetic material, e.g. virus-transformed cells

C12N 07/00

115

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12):
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or
purification thereof

C12N 07/01

63

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12):
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or
purification thereof (C12N 07/00): Viruses, e.g. bacteriophages,
modified by introduction of foreign genetic material

C12N 07/02

65

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12):
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or
purification thereof (C12N 07/00): Recovery or purification

C12N 07/04

53

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12):
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or
purification thereof (C12N 07/00): Inactivation or attenuation;
Producing viral sub-units

C12N 15/09

34

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12):
Mutation or genetic engineering; DNA or RNA concerning genetic
engineering, vectors, e.g. plasmids, or their isolation, preparation
or purification; Use of hosts therefor (C12N 15/00): Recombinant
DNA-technology

C12N 15/44

40

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12):
Mutation or genetic engineering; DNA or RNA concerning genetic
engineering, vectors, e.g. plasmids, or their isolation, preparation
or purification; Use of hosts therefor (C12N 15/00): Recombinant
DNA-technology (15/09): DNA or RNA fragments; Modified forms
thereof (15/11): Genes encoding microbial proteins, e.g.
enterotoxins (15/31): Genes encoding viral proteins (15/33):
Proteins from RNA viruses, e.g. flaviviruses (15/40):
Orthomyxoviridae, e.g. influenza virus

92

C12N 15/63

23

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12):
Mutation or genetic engineering; DNA or RNA concerning genetic
engineering, vectors, e.g. plasmids, or their isolation, preparation
or purification; Use of hosts therefor (C12N 15/00): Recombinant
DNA-technology (15/09): Introduction of foreign genetic material
using vectors; Vectors; Use of hosts therefor; Regulation of
expression

C12N 15/86

27

BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY;
ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING (C12):
Mutation or genetic engineering; DNA or RNA concerning genetic
engineering, vectors, e.g. plasmids, or their isolation, preparation
or purification; Use of hosts therefor (C12N 15/00): Recombinant
DNA-technology (15/09): DNA or RNA fragments; Modified forms
thereof (15/11): Vectors or expression systems specially adapted
for eukaryotic hosts (15/79): for animal cells (15/85): Viral vectors

Top DWPI Classification v. Patent Document Count
The DWPI classification system uses a simple way of categorizing patent documents. This
system was developed by Thomson Scientific to facilitate searching of a particular area of a
given technology by providing a smaller initial pool of documents to search. As per this system,
patents are broadly divided into three areas: Chemical, Engineering, and Electronic and
Electrical Engineering. Each of these is then further divided into Sections and Classes which
describe the technical area, or areas, covered by the patent.
The pattern of top DWPI codes was similar for the vaccine category and the supporting
technologies category, as shown in Figure 21. Among codes representing at least 10 families
each, the top three codes for both categories was B04, which covers polymers such as
polypeptides, D16, which covers cultures of cell lines or yeast, and C06, which covers
production of recombinant proteins in plants and veterinary vaccines. Full definitions of the
codes are given in Table XI.
There were only minor differences between the two categories, perhaps because the DWPI codes
represent fairly broad areas of technology and cannot distinguish among the various categories
used to delineate the results presented herein. Overall this particular analysis was very useful.
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Figure 22. Top DWPI Classes for Both Vaccines and Supporting Technology Documents.
Table XI. Definitions of the Top DWPI Classes.
DWPI
Class
A96
B00

Vaccines

Supporting
Technology

B03
B04

55
0
0
534

B05

13

13 Pharmaceuticals: Other organics - aromatics, aliphatic, organometallics, compounds whose substituents vary such that they
would be classified in several of B01 - B05.

B07

37

26 Pharmaceuticals: General - tablets, dispensers, catheters (excluding
drainage and angioplasty), encapsulation etc, but not systems for
administration of blood or saline or IV feeding etc.

0

34 Agricultural Chemicals: Other organic compounds, inorganic
compounds and multi-component mixtures. Polymers and proteins.

154

248 Agricultural Chemicals: Biotechnology - including plant genetics and
veterinary vaccines.

C03
C06

81
16
10
671

Class Definition
Polymers and Plastics: Medical, dental, veterinary, cosmetic
Pharmaceuticals
Pharmaceuticals: Other heterocyclics
Pharmaceuticals: Natural products and polymers. Including testing
of body fluids (other than blood typing or cell counting),
pharmaceuticals or veterinary compounds of unknown structure,
testing of microorganisms for pathogenicity, testing of chemicals
for mutagenicity or human toxicity and fermentative production of
DNA or RNA. General compositions.
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D16

517

640 Food, Detergents, Water Treatment and Biotechnology:
Fermentation industry - including fermentation equipment,
brewing, yeast production, production of pharmaceuticals and
other chemicals by fermentation, microbiology, production of
vaccines and antibodies, cell and tissue culture and genetic
engineering.

P34

10

0 General Engineering: HEALTH, AMUSEMENT: Sterilising, syringes,
electrotherapy

S03

15

29 Instrumentation, Measuring and Testing: Scientific Instrumentation
(G01J, K, N, T-W) Photometry, calorimetry. Thermometers.
Meteorology, geophysics, measurement of nuclear or X-radiation.
Investigating chemical or physical properties.

T01

10

0 Computing and Control: Digital Computers (G06C-F) Electronic data
processors, interfaces and programme control. Mechanical digital
computers.

Top Derwent Manual Codes v. Patent Document Count
The Derwent Manual Code represents a further level of classification that provides more
specificity to the DWPI Codes.145 Again, patent families often had multiple different Manual
Code associated with them, and each code was taken for analysis. Among vaccine documents,
24 different Manual Codes each represented more than 50 INPADOC families, as shown in
Figure 22. The top three codes were D05-H07, which concerns production of vaccines, B14S11D3, which concerns genetically engineered vaccines, and B14-A02B2, which concerns
orthomyxoviruses. The definition of top Manual Codes are given in Table XII.
Once again, the supporting technologies category was covered by more Manual Codes than the
vaccine category was. Thirty-six different Manual Codes were applied to 50 or more INPADOC
families, as shown in Figure 23. D05-H07 and B14-A02B2 were again among the top three
codes, but the second most prominent code for the supporting technologies was B14-S11A,
which concerns antiviral vaccines. Additional Manual Codes appearing in association with
supporting technology documents was B04-F0100E, D05-H08, and D05-H14, which all concern
transformed cell lines such as those used to produce recombinant viruses or subunits, and B14S12, which concerns veterinary pharmaceuticals such as vaccines. In general the supporting
technologies documents had more Manual Codes in the C04 and C14 classes, which cover
veterinary uses of pharmaceuticals. Thus, the differences in the Manual Codes represent the
different subcategories under the vaccine and supporting technology headings.

145

http://www.stn-international.de/dwpi_manual_codes/A.html.
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Derwent Manual Code

Vaccine Documents - Top Derwent Manual Codes
A12-V01
B04-B04C1
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Figure 23. Top Derwent Manual Codes representing at least 50 vaccine documents.
Table XII. Definitions of Top Derwent Manual Codes for Vaccine Documents.
DWPI
Manual
Codes

# Docs.

D05-H12F

68

D05-H12E
D05-H12A

111
70

D05-H07

446

C14-S11A
C14-G01
C14-A02B2
C04-B04C1
B14-S11D3
B14-S11D2

130
62
95
50
112
60

Code Description

Food, Detergents, Water Treatment and Biotechnology: RECOMBINANT
VIRUSES [EXCLUDING VIRAL VECTORS]
Food, Detergents, Water Treatment and Biotechnology: VECTORS
Food, Detergents, Water Treatment and Biotechnology: WILD-TYPE CODING
SEQUENCES
Food, Detergents, Water Treatment and Biotechnology: PRODUCTION OF
VACCINES, ANTIGENS
Agricultural Chemicals: ANTIVIRAL VACCINE
Agricultural Chemicals: IMMUNOSTIMULANT GENERAL AND OTHER
Agricultural Chemicals: (PARA/ORTHO)MYXOVIRUS
Agricultural Chemicals: MICROBIAL ANTIGEN
Pharmaceuticals: SYNTHETIC/GENETICALLY ENGINEERED VACCINE
Pharmaceuticals: LIVE-ATTENUATED (WEAKENED) VACCINE
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B14-S11A
B14-S11
B14-G01
B14-A02B2
B14-A02
B04-N03
B04F11B0E
B04-F11B
B04F1100E
B04-F11
B04-E99
B04-E08
B04-B04C1
A12-V01

415
52
181
322
60
69
52

Pharmaceuticals: ANTIVIRAL VACCINE
Pharmaceuticals: VACCINE [GENERAL]
Pharmaceuticals: IMMUNOSTIMULANT GENERAL AND OTHER
Pharmaceuticals: (PARA/ORTHO)MYXOVIRUS
Pharmaceuticals: ANTIVIRAL [GENERAL]
Pharmaceuticals: MICROORGANISM PROTEIN/POLYPEPTIDE (NO SEQUENCE)
Pharmaceuticals: RNA VIRUS GENERAL (GENETICALLY ENGINEERED)

80
51

Pharmaceuticals: RNA VIRUS GENERAL
Pharmaceuticals: VIRUSES (GENETICALLY ENGINEERED)

53
68
125
172
52

Pharmaceuticals: VIRUSES
Pharmaceuticals: PATENT WITH GENESEQ RECORD
Pharmaceuticals: VECTORS, PLASMIDS, COSMIDS, TRANSPOSONS
Pharmaceuticals: MICROBIAL ANTIGEN
Polymers and Plastics: MEDICINES, PHARMACEUTICALS
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Derwent Manual Code

Supporting Technologies - Top Derwent Manual
Codes
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Figure 24. Top Derwent Manual Codes representing at least 50 supporting technology
documents.
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Table XIII. Definitions of Top Derwent Manual Codes for Supporting Technology Documents.
DWPI Manual
Codes

# Docs

Code Description

D05-H14

71 Food, Detergents, Water Treatment and Biotechnology: RECOMBINANT
CELLS

D05-H12F

107 Food, Detergents, Water Treatment and Biotechnology: RECOMBINANT
VIRUSES [EXCLUDING VIRAL VECTORS]

D05-H12E
D05-H12A

134 Food, Detergents, Water Treatment and Biotechnology: VECTORS
73 Food, Detergents, Water Treatment and Biotechnology: WILD-TYPE
CODING SEQUENCES

D05-H08

65 Food, Detergents, Water Treatment and Biotechnology: CELL OR TISSUE
CULTURE

D05-H07

532 Food, Detergents, Water Treatment and Biotechnology: PRODUCTION OF
VACCINES, ANTIGENS

D05-H06A

55 Food, Detergents, Water Treatment and Biotechnology: NEWLY
DISCOVERED, TESTING OF, ISOLATION OF, IDENTIFICATION OF AND
DETECTION OF VIRUSES

D05-H06

52 Food, Detergents, Water Treatment and Biotechnology: NEWLY
DISCOVERED, TESTING OF, ISOLATION OF, IDENTIFICATION OF AND
DETECTION OF VIRUSES AND OTHER

C14-S12
C14-S11D3

76 Agricultural Chemicals: VETERINARY
103 Agricultural Chemicals: SYNTHETIC/GENETICALLY ENGINEERED VACCINE

C14-S11A
C14-G01
C14-A02B2
C04-F11B0E

208
67
140
53

C04-F11B
C04-E99
C04-E08
C04-B04C1
B14-S12
B14-S11D3
B14-S11D2
B14-S11D1
B14-S11A
B14-G01
B14-A02B2
B14-A02
B04-F11B0E

Agricultural Chemicals: ANTIVIRAL VACCINE
Agricultural Chemicals: IMMUNOSTIMULANT GENERAL AND OTHER
Agricultural Chemicals: (PARA/ORTHO)MYXOVIRUS
Agricultural Chemicals: RNA VIRUS GENERAL (GENETICALLY ENGINEERED)

53 Agricultural Chemicals: RNA VIRUS GENERAL
50 Agricultural Chemicals: PATENT WITH GENESEQ RECORD
66 Agricultural Chemicals: VECTORS, PLASMIDS, COSMIDS, TRANSPOSONS
69
84
163
72
55
454
156
303
71
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Agricultural Chemicals: MICROBIAL ANTIGEN
Pharmaceuticals: VETERINARY
Pharmaceuticals: SYNTHETIC/GENETICALLY ENGINEERED VACCINE
Pharmaceuticals: LIVE-ATTENUATED (WEAKENED) VACCINE
Pharmaceuticals: WHOLE-KILLED (INACTIVE) VACCINE
Pharmaceuticals: ANTIVIRAL VACCINE
Pharmaceuticals: IMMUNOSTIMULANT GENERAL AND OTHER
Pharmaceuticals: (PARA/ORTHO)MYXOVIRUS
Pharmaceuticals: ANTIVIRAL [GENERAL]
Pharmaceuticals: RNA VIRUS GENERAL (GENETICALLY ENGINEERED)
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B04-F11B
B04-F1100E
B04-F11
B04-F0100E

121
64
89
74

Pharmaceuticals: RNA VIRUS GENERAL
Pharmaceuticals: VIRUSES (GENETICALLY ENGINEERED)
Pharmaceuticals: VIRUSES
Pharmaceuticals: CELLS, MICROORGANISMS, TRANSFORMANTS, HOSTS,
CELL LINES, TISSUE [GENERAL] (GENETICALLY ENGINEERED)

B04-E99
B04-E08
B04-B04C1
B02-V

69
149
130
89

Pharmaceuticals: PATENT WITH GENESEQ RECORD
Pharmaceuticals: VECTORS, PLASMIDS, COSMIDS, TRANSPOSONS
Pharmaceuticals: MICROBIAL ANTIGEN
Pharmaceuticals: VACCINES AND ANTIBIOTICS BEGINNING WITH THE
LETTER "V", GENERAL VACCINES

A12-V01

66 Polymers and Plastics: MEDICINES, PHARMACEUTICALS
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Conclusions
A search of the patent literature for publications containing keywords related to the influenza
virus returned approximately 33,500 total documents representing almost 3,800 patent families.
However, only about one-half of those patent documents will actually be specific for
prophylactic influenza A vaccines or for technologies that are used in the manufacture of
vaccines. Of those relevant documents, approximately 10-15% are specifically related to
pandemic influenza, although the remainder could probably be applied to pandemic strains.
Thus, influenza vaccine technologies are disclosed in a fairly small set of patent documents,
especially considering that influenza virus infections have been a global threat to human health
for at least century.
However, filing of applications related to influenza have been steadily increasing in the last
decade, so there are many new technological advances that have yet to be fully tested in the
clinic for effectiveness against influenza. Much of the increase in filings is in response to recent
influenza outbreaks: the H5N1 (bird flu) epidemic that began in 1997 and continued for a
decade, and the H1N1 (swine flu) pandemic that was first diagnosed in 2009.
Influenza virus technologies appear to originate from a small set of countries, mostly the United
States, Great Britain, France, China, Japan, Korea, and Russia. Protection for influenza vaccine
intellectual property has been sought worldwide. However, except for Brazil coverage in South
America is quite minimal, and except for South Africa protection for these technologies is sparse
in Africa.
Top assignees for the relevant families were mostly large pharmaceutical companies, with the
majority of patent families coming from Novartis, followed by GlaxoSmithKline, Pfizer, U.S.
Merck (Merck, Sharpe, & Dohme), Sanofi, and AstraZeneca. Governmental and nonprofit
institutes in China, Japan, Russia, South Korea and the United States also are contributing
heavily to influenza vaccine research.
Progress is being made towards the development of an effective vaccine against pandemic
influenza strains, but much work remains to be done, especially testing these novel vaccines in
the clinic. Additionally, this much-needed technology is not adequately distributed to the leastdeveloped nations. Once a new pandemic strain arises, infections could rapidly spread over an
extensive area, so more thorough global preparedness is needed to prevent the health crisis this
pathogen still poses.
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Appendix Materials
APPENDIX A: Master Coding Spreadsheet (electronic version only).
This Excel file describes coding of representative INPADOC family members, with notes on the
basis of the coding decisions. The first sheet is organized by publication number, and the second
sheet shows the publication numbers which fell in each category. The third sheet shows the
consolidated major categories.

APPENDIX B: Platform Technologies Documents: Full Records (electronic version only).
This Excel file has detailed information of each relevant patent family in this category. The full
records, containing all available information extracted from Thomson Innovation, are given for
each representative family member. Documents are organized alphabetically by publication
number.

APPENDIX C: Vaccine Documents: Full Records (electronic version only).
This Excel file has detailed information of each relevant patent family in this category. The full
records, containing all available information extracted from Thomson Innovation, are given for
each representative family member. The first sheet has documents organized alphabetically by
publication number. Subsequent sheets show the data manipulations used to determine priority
countries, publications by year, major classifications, and family size. Analyses of assignees,
inventors, and top multi-jurisdictional filers are shown in separate files, as given below.

APPENDIX D: Supporting Technologies Documents: Full Records (electronic version
only).
This Excel file has detailed information of each relevant patent family in this category. The full
records, containing all available information extracted from Thomson Innovation, are given for
each representative family member. The first sheet has documents organized alphabetically by
publication number. Subsequent sheets show the data manipulations used to determine priority
countries, publications by year, and major classifications. Analyses of assignees and inventors
are shown in separate files, as given below.
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APPENDIX E: Top Multi-Jurisdictional Filings Spreadsheet (electronic version only).
This Excel file has representative family members ranked according the size (number of
publications) of the INPADOC family each document represents. The top 21 largest families are
then analyzed based on the total number of jurisdictions in which each family has been filed.
Data is assembled from INPADOC, DWPI and TotalPatent family data. Note that this analysis
was performed for vaccine documents only.
APPENDIX F: Assignees Analysis Spreadsheet (electronic version only).
Assignee data for each representative family member was manually corrected to reflect changing
company names or the acquisition of an assignee by another company. This Excel file details
assignee data first by publication number, and then assignees are shown by total number of
families believed to be owned by that assignee. Both vaccines and supporting technology
documents were pooled together to generate an assignee list covering all highly relevant
documents. The website for each assignee is also given, if possible.
Appendix G: Alternative Assignee Names and Subsidiaries Spreadsheet (electronic version
only).
The names of assignee companies can often change, particularly following mergers and
acquisitions. This data has been manually assembled as much as possible, and this Excel file
details the alternative names and subsidiaries under which a given assignee may appear.
Appendix H: Vaccine Inventors Spreadsheet (electronic version only).
This Excel file separates each representative family member by the individual inventors listed in
the record. The top inventors who are listed on the most patent publications are then given.
Note that inventor names are often misspelled, have variable middle names, or have first and last
names switched. For those reasons, the accuracy of this data cannot be entirely assured.
Appendix I: Supporting Technology Inventors Spreadsheet (electronic version only).
This Excel file separates each representative family member by the individual inventors listed in
the record. The top inventors who are listed on the most patent publications are then given.
Note that inventor names are often misspelled, have variable middle names, or have first and last
names switched. For those reasons, the accuracy of this data cannot be entirely assured.
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Appendix J: PDF Files of Representative Patent Documents (electronic version only).
This folder contains the pdf files for each representative family member, if available. Subfolders
are given for each of the Vaccine and Supporting Technologies categories, but not Platforms.
Note that in a few instances a pdf file of the representative family member was not available.
Thus these folders do not contain the complete number of representative documents.

Appendix K: PDF Files of Selected Non-Patent Literature (electronic version only).
This folder contains pdf files for selected non-patent literature relevant to prophylactic influenza
A vaccines. An extensive search of NPL was not performed; rather the documents included in
this folder are mostly review articles which reveal the general state of the art, summarize
available technologies, or discuss strategic approaches to immunization. Given the rate at which
influenza vaccine technologies have been changed, reviews were only selected from those
published within the last five years in order to present only the most up-to-date articles.

Appendix L: PDF Files of This Report (electronic version only).
This folder contains separate pdf files of this report and the cover to the report. The ITTI Clinic
wishes for this report to be as widely disseminated as possible, so that all interested parties may
have access to the information presented herein. However, anyone is free to base a subsequent
report on our work as long as proper attribution is given to ITTI.
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Appendix M: Keywords Used in Searching.
The following represents the keywords used by the team members in patent database searching.
Note that each team member used different combinations of these terms, and only a subset of
terms was used for any particular search.


Influenza
o Pandemic
 Swine
 Avian
 Bird
o H5N1
o H1N1
o H{d}N{d} (TI)
o Orthomyxovir* (TI) Orthomyxovir! (TP)
o HPAI (Highly Pathogenic Avian Influenza)
o Hemagglutinin (Haemagglutinin)
o Neuraminidase
o Epidemic
o !Virulen! *Virulen*
o highly pathogenic
o Pathogen! Pathogen*
o (negative strand RNA virus)



Vaccine
o Immun! (TP) Immun* (TI)
o Immunologic! Immunologic*
o Immunostimul! or immuno-stimul!
o Immunomodul! or immuno-modul!
o Immunologentic
o Immunogen! Immunogen*
o Immuniz! Immuniz
o Vaccin! (TP) Vaccin* (TI)
o Virotherap! Virotherap*
o Prophyl! Prophyl*
o Antigen! Antigen*
 Epitope! Epitope*
 Determinant
o Antiinfective or anti-infective (sp?)
o Antiviral or anti-viral or anti viral
o Viricide or Virucide
o Prevent! Prevent*
o Phage
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Appendix N: Notes on Patent Families.
If there are several applications or publications for an individual invention (in other countries)
claiming the same priority or priorities and originating from the same inventors, those documents
constitute a “patent family.” All of the family members are related to one another by common
priority publications with associated priority dates. INPADOC families are organized solely on
priority data, whereas DWPI families focus on the inventions such that divisional applications of
a single priority document are considered to be in different patent families. Further, Lexis
TotalPatent reports “extended families” which are similar to INPADOC families but include
more jurisdictions.
The concept of the patent family first emerged through the Paris Convention on the Protection of
Intellectual Property in 1883, while automated systems enabling patent family searching became
available through the establishment of the IIB in The Hague in 1947and INPADOC in Vienna in
1972. Since then, patent searching has evolved due to exponential improvements in computing
and communication technology.
The term patent family can be defined in a number of ways depending on the relationship
between a patent document and its priority or priorities within the meaning of the Paris
Convention. The differences only become obvious when the structure of a patent application is
complex, i.e. when applications are filed in several countries. Such applications may cite various
earlier applications as priorities, or the different patent offices involved in the grant process may
accept or refuse different patent claims. This results in patents which have different scopes of
protection.
An important point when using any database to retrieve information on patent families is that
there is never any guarantee that you will find all the corresponding patent documents that exist.
Database producers do what they can to ensure completeness, but they can never guarantee it.” 146
The “Extended” (INPADOC) Patent Family
“The biobibliographic and legal status databases form the basis of the EPO’s raw data resources
(INPADOC). In February 2008 the bibliographic data included about 60 million bibliographic
data sets from almost 80 different countries. The legal status database contains a collection of
more than 50 million legal events from 48 countries.
From the beginning, the concept was to cover as many countries and as many publication levels
as possible. One of the strongest motives for the integration of INPADOC into the EPO was the
146

EUROPEAN PATENT OFFICE, Patent Families (Feb. 29, 2008), http://www.epo.org/patents/patentinformation/about/families.html.
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wish to combine the particular strengths of INPADOC with the EPO’s existing in-house
bibliographic database, “DOC-DB.”
Following integration of the two databases in the 1990s, the raw data behind both databases is
now the same. And since esp@cenet draws on the same pool of data as raw data resources
(INPADOC) and DOC-DB, it contains the same documentation.
However, the philosophy of the “extended” (INPADOC) patent family is quite different, and so
are the results of family searches. Unlike the “also published as” feature in esp@cenet, which
only shows “equivalents,” i.e. almost identical documents, an INPADOC family search should
retrieve all documents relating in any way to the root document.
Features of INPADOC
When using INPADOC via one of the commercial database host services, it bears all the
esp@cenet features, plus the following:





Standardization of applicant and inventor names
References to abstracts from Chemical Abstracts and Thomson Scientific
Abstracts are made within the patent family
By including the legal status database additional information is available and
additional family links can be established
National application numbers, international application numbers and domestic
relations are included in the family search

For both of the EPO’s raw data resources (INPADOC) and esp@cenet, even where no priority
has been claimed by the patent application, artificial or “intellectual” links are built in systematic
way for the complete PCT minimum documentation. The same is done for older documents
(pre-1968) for which the priority information is not complete.
Definition of the “extended” (INPADOC) patent family
All the documents directly or indirectly linked via a priority document belong to one patent
family. In the case shown below, documents D1 to D5 belong to the same patent family, P1.
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FAMILY P1
Document D1
Document D2
Document D3
Document D4
Document D5

Priority P1
Priority P1
Priority P1

Priority P2
Priority P2
Priority P2

Priority P3
Priority P5

As mentioned above, national patent application numbers, international application numbers and
domestic relations are included in the family search.
In the “extended” (INPADOC) patent family, it does not matter where a search is started. It can
be an application number, a priority application number or a publication number.
If the search starts with a publication number, all application numbers, domestic application
numbers, priority numbers and international application numbers are used to retrieve additional
documents. For all documents found in this step, step one is repeated. This iteration process
ends only when no more new documents can be found.
Raw data resources (INPADOC) also use some additional sophisticated rules for certain
countries, for example, if publication numbers are used instead of priority numbers in the
original documents. This happened rather frequently for older documents, where the priority
claims were not treated as carefully as they are now. The inclusion of legal status information in
the patent search also sometimes retrieves additional links, e.g. for divisional applications,
continuations, continuations in part or national publications of first filings of PCT (international)
applications, where the priority links are often missing.
Limitations of the family search in raw data resources (INPADOC) have to rely on the
correctness of the data supplied by the co-operating patent offices and the extent to which it is up
to date. In particular, delays in the delivery of bibliographic data can vary significantly
depending on the country concerned and the time period covered. Before relying on the
completeness of a patent family, users should check where there are gaps or delays in certain
areas. This kind of information can be found in the PFS and PRS statistics on the internet, which
are updated weekly and contain indications of missing or delayed document series. See raw data
resources (INPADOC) useful tables and statistics. To be absolutely sure about the actual status
of a patent, users are recommended to contact the appropriate patent issuing authority direct.
Particular care has to be taken in the case of European patents which have entered into the
national phase. The completeness and accuracy of data can vary significantly from country to
country. A good overview of the volume and kind of "post-grant" information available in raw
data resources (INPADOC) can be found in the raw data resources (INPADOC) FAQ. For most
of the EPO member states, information about the validation, lapse, etc., of European patents is
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given as part of the legal status information, and as mentioned before is less consistent due to the
different quality of data available. Starting from week 50/2007, additional post-grant
information is taken from the fee administration system and included in the legal status part of
the database.
Thomson Scientific WPI Patent Family (DWPI)
“Patent Families in the Thomson Scientific World Patents Index (WPI) draw together patents
covering the same invention. Their relationship is defined by the priority or application details
claimed by each document. Thus, in its simplest form, a new document (D1) claiming a unique
priority (P1) will be assigned to be the basis of its own, new patent family in Thomson Scientific
WPI.
Subsequently, if a second document (D2) also claiming priority P1 is received by Thomson
Scientific this will be added (as an ―equivalent‖) to the patent family already containing
document D1. Other documents claiming priority P1 will also be added to this family as
―equivalents as they are included in the database. Thus, a patent family may contain anything
from a single document to 10 or more. Each patent family represents a single record in the
Thomson Scientific WPI database.
The basic document is the first member of a patent family that appears in Thomson Scientific
WPI, so it may not necessarily be the first one published for that invention. Differences in the
speed that patenting authorities supply data to Thomson Scientific and in the processing time for
documents from different countries may affect which document appears in Thomson Scientific
WPI first and becomes basic.
Patents often claim more than a single priority and these must match before any equivalent is
added to a family. This means that if a basic document (D3) claims priorities P2, P3 & P4, a
subsequent document (D4) claiming priorities P2 & P3 will be added to the family as an
equivalent, whereas patent D5 which claims priorities P2, P3 and a unique priority (P5) will form
the basis of a new, but related patent family. In cases such as this, the accession number of any
related family is included in the cross-reference field of each relevant Thomson Scientific WPI
record.
Divisions and continuation patents maintain the same status as the original specification. This
means that if GB1 is a basic, and GB2 is divisional to GB1, then GB2 will also be a basic (in its
own family). However, if GB1 is equivalent to another document already in the Thomson
Scientific WPI database, then GB2 will also join this family as an equivalent. It should be noted
that family relationships will be defined by the order in which patents appear in Thomson
Scientific WPI.
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Thomson Scientific also puts a lot of resources into including patents in families even when no
foreign priority is claimed, e.g. when an application has been made beyond the 12 months
defined by the Paris Convention. Thomson Scientific identifies these "non-convention"
equivalents by the presence of foreign nationals and addresses in the Inventor field in the
absence of priority data other than the local filing details. Equivalency is determined through a
time-consuming manual check of inventors, subject matter, etc.
In this way Thomson Scientific attempts to make patent families in Thomson Scientific PI as
comprehensive as possible. However, because of the incidence of multiple priorities, and patent
divisions and continuations (especially continuing applications in US documents), it is important
to retrieve all related families through their common priorities in order to have a comprehensive
overview of patent family relationships.”147

APPENDIX O: Notes on Major Classifications.
US Classifications148
The U.S. Patent Classification System is a categorization of all U.S. patent and other technical
documents by common subject matter. Each subject matter division includes a class and a
subclass. The Manual of Classification is an ordered listing of all the valid classifications.
Classes and subclasses have titles providing a general description of their contents, and
definitions providing a more specific description. A definition may contain an explanation of the
class or subclass, a glossary, search notes, references to subclasses within a class, and references
to other classes and subclasses. The U.S. system contains about 450 classes and about 150,000
subclasses. The classification code is express with 2 numbers separated by a forward slash, for
example, 435/134. The first number, 435, represents the class of the invention. The number
following the slash, 134, is the subclass of the invention within the preceding class. Patents will
always have both a class and a subclass. More explanation and definitions of U.S. patent
classifications can be found at, http://www.uspto.gov/web/patents/classification/.

147
148

Id.
http://www.uspto.gov/web/patents/classification/.
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International Patent Classification System149








The World Intellectual Property Organization (WIPO) administers the International
Patent Classification (IPC) system. IPCs are organized hierarchically and divide
technology into eight sections (A through G) with approximately 70,000 subdivisions.
An IPC is typically expressed as, for example, C12N 15/82, but may also appear as
C12N001582.
o The first letter, C, specifies a Section.
o The number following the Section indicator, 12, specifies a Class.
o The letter N specifies a Subclass.
o The number 15 specifies a Main Group.
o The number following the slash, 82, specifies a Subgroup.
WIPO publishes the authentic IPCs versions in English and French languages. Chinese,
Croatian, Czech, Dutch German, Hungarian, Japanese, Korean, Polish, Romanian,
Russian, Serbian, and Spanish versions are also available.
More information is available at the WIPO website,
http://www.wipo.int/classifications/ipc/en/.

Description of Derwent Patent Classifications150
 The Derwent World Patent Index (DWPI) classification system categorizes patent
documents using a simple classification system for all technologies; consistently applied
to all patents by Thomson Scientific subject experts, enabling effective and precise
searching in a particular area of technology.
 International Patent Classification (IPC) is an internationally recognized classification
system controlled by the World Intellectual Property Organization (WIPO) and assigned
to patent documents by various patent offices.
 Where possible Thomson indicated next to the class the equivalent IPC in an abbreviated
form (e.g., A47, F23-5). However, this should be used only as a guide since there are
areas where the DWPI classes are assigned intellectually by Thomson’s subject experts,
and no strict correspondence is claimed.

Appendix P: Authors’ Resumes
Resumes for each of the four team members follow.
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WIPO, http://www.wipo.int/classifications/ipc/en/.
Derwent World Patent Index, THOMSON CORPORATION,
http://science.thomsonreuters.com/m/pdfs/mgr/derwentclass.pdf.
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DAVID L. PFLUGH, PH.D.
david.pflugh@law.unh.edu
203.816.7870

1 Merrimack St., Apt. 1B, Concord, NH 03301

CERTIFICATION
United States Patent and Trademark Office: Registration Number 64,039

EDUCATION
Franklin Pierce Center for Intellectual Property - University of New Hampshire School of Law
JD candidate, Class of 2013, 3.31 GPA
Earned Patent Literature Searching Certificate (trained in patent database searching)
Relevant coursework includes: Patent Law, Patent Claim Drafting, Technology Licensing,
Copyright Law, International Intellectual Property, Pharmaceutical Patent Law,
Global IP Management, Patent Reexamination & Post-Grant Procedures, and
Advanced Patent Law Seminar with retired Federal Circuit Judge Arthur Gajarsa
University of Kentucky, Ph.D., Immunology, 1995, 3.9 GPA
Pennsylvania State University, BS with High Honors, Molecular & Cell Biology, 1987, 3.8 GPA

PROFESSIONAL EXPERIENCE
OFFICE of INNOVATION DEVELOPMENT & COMMERCIALIZATION,
UNIVERSITY at ALBANY
January – August 2012
In association with Heslin Rothenberg Farley & Mesiti, P.C.
• Extern/Intern
Analyzed invention disclosures: interviewed inventors, prepared patentability reports
Drafted response to International Search Report and assisted with USPTO Office Actions
Prepared Patent Landscape Report and US Provisional Patent Application
INTERNATIONAL TECHNOLOGY TRANSFER CLINIC, UNH SCHOOL OF LAW
Fall 2012 (Project Director): Preparing patent landscape report regarding pandemic influenza
vaccines for the World Intellectual Property Organization;
Summer 2011: Refined and modified a protocol designed to assist developing nations in
identifying patents encompassing drugs on the Essential Medicines List. Reported to WIPO.
Professional Tutor
Provided standardized test preparation; Teaching subjects at high school & college level

2009 - 2011

CENTOCOR, A Johnson & Johnson Pharmaceuticals Company
• Research Scientist:
Conducted biologics drug development in immunology and pulmonary biology
Provided expert scientific analysis of proposals for licensing and partnering opportunities

2005 – 2008

YALE UNIVERSITY SCHOOL OF MEDICINE
• Postdoc & Associate Research Scientist in Immunobiology & Orthopaedics

1995 – 2005
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PROFESSIONAL ACTIVITIES
American Intellectual Property Law Association, 2010 – present
Association of University Technology Managers (AUTM), 2011 - present
Licensing Executive Society, 2010 – present
President, LES student chapter at UNH School of Law
Patent Information Users Group, 2009 - present

COMMUNITY INVOLVEMENT & VOLUNTEER ACTIVITIES
Planning Commission, Caln Township, PA, 2008 – 2011
Inspector of Elections, Caln Township Precinct 1, Thorndale, PA, 2006, 2008, 2009
Justice of the Peace, State of Connecticut, 2005
Member of the Board of Education, City of Derby, CT, 2005 – 2006
President of the Board of Directors of Lincoln Senior Housing, Inc., 2004 – 2006
Founder of a 501(c)(3) non-profit organization. Personally managed a $3.8 million construction
project that provided subsidized housing for senior citizens.

PUBLICATIONS













M.C. Horowitz, A.L.M. Bothwell, D.G.T. Hesslein, D.L. Pflugh, and D.G. Schatz. 2005. B cells and
osteoclast and osteoblast development. Immunological Reviews 208:141.
M.C. Horowitz, Y. Xi, D.L. Pflugh, D.G.T. Hesslein, D.G. Schatz, J.A. Lorenzo, and A.L.M. Bothwell.
2004. Early onset osteopenia with increased osteoclast progenitors in Pax5 deficient mice. Journal of
Immunology 173:6583.
V. Giambra, S. Volpi, A.V. Emelyanov, D. Pflugh, A. Bothwell, P. Norio, Y. Fan, Z. Ju, A.I. Skoultchi,
R.R. Hardy, D. Frezza, and B.K. Birshtein. 2008. Pax5 and linker histone H1 coordinate DNA methylation
and histone modifications in the 3' regulatory region of the immunoglobulin heavy chain locus. Mol. Cell.
Biol. 28:6123.
K. Johnson, D.L. Pflugh, D. Yu, D.G.T. Hesslein, K.-I. Lin, A.L.M. Bothwell, A. Thomas-Tikhonenko,
D.G. Schatz, and K. Calame. 2004. B-cell specific loss of histone 3 lysine 9 methylation in the VH locus
depends on Pax5. Nature Immunology 5:853.
M.J. Fernandez-Cabezudo, C. Vijayasarathy, D.L. Pflugh, A.L.M. Bothwell, and B.K. al-Ramadi. 2004.
Evidence for a dual pathway of activation in CD43-stimulated Th2 cells: Differential requirements for the
lck tyrosine kinase. International Immunology 16:1215.
D.G.T. Hesslein, D.L. Pflugh, D. Chowdhury, A.L.M. Bothwell, R. Sen, and D.G. Schatz. 2003. Pax5 is
required for recombination of transcribed, acetylated, 5’ IgH V gene segments. Genes & Dev. 17:37.
D.L. Pflugh, S.E. Maher, and A.L.M. Bothwell. 2002. Ly-6 Superfamily members Ly-6A/E, Ly-6C, and
Ly-6I recognize two potential ligands expressed by B lymphocytes. Journal of Immunology 169: 5130.
D.L. Pflugh, S.E. Maher, and A.L.M. Bothwell. 2000. Ly-6I, a new member of the murine Ly-6
superfamily with a distinct pattern of expression. Journal of Immunology 165: 313.
S.E. Maher, D.L. Pflugh, N.J. Larsen, M.F. Rothschild, and A.L.M. Bothwell. 1998. Structure/function
characterization of porcine CD59. Transplantation 66: 1094.
J. S.Bryson, CD. Jennings, D.M. Lowery, S.L. Carlson, D.L. Pflugh, B.E. Caywood, and A.M. Kaplan.
1999. Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versushost disease. Bone Marrow Transplantation 23: 363.
J.S. Bryson, H. Lake-Bullock, D.L. Pflugh, C.D. Jennings, P.M. Stuart, B.E. Caywood, and A.M. Kaplan.
1995. In vivo reactivity of T cell clones isolated from mice with syngeneic graft-versus-host disease.
Transplantation 60: 171.
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JEREMY B. BARTON
USPTO Reg. 67,963
18A Charles Street ▪ Concord, NH 03301 ▪ jeremybarton19@gmail.com

BAR ADMISSIONS
United States Patent and Trademark Office (Reg. 67,963)
EDUCATION
University of New Hampshire School of Law (formerly Franklin Pierce Law Center), Concord,
NH
Juris Doctor Candidate, May 2013
Top 10% of Class, Dean’s Merit Scholar
Senior Editor, IDEA: The Intellectual Property Law Review
Faculty Assistant for Prof. John Orcutt’s Contracts course (Fall 2011)
University of Utah, Salt Lake City, UT
Bachelor of Science, Biomedical Engineering, May 2007
Emphasis in Mechanical Engineering
Phi Theta Kappa Honor Society and Motor Board Honor Society
LEGAL EXPERIENCE
May to July Oblon, Spivak, McClelland, Maier, and Neustadt, LLP
2012
Summer Associate:
Prepare responses to Office Actions, draft internal legal memos, and conduct legal research
concerning pending litigation.
Jan. to May Chief Judge Randall R. Rader, U.S. Court of Appeals for the Fed. Cir.,
Washington, DC
2012
Judicial Clerk Extern
Researched and drafted bench memoranda, presented cases to Judge Rader at clerk meetings, and
prepared preliminary opinion drafts.
June to Aug. U.S. Patent and Trademark Office, Alexandria, VA
2011 Intern for the PCT Legal Office
Received patent examiner training. Worked on a major research project comparing the
treatment of corresponding international patent applications by an International Searching
Authority with the treatment in the national phase by the USPTO.
TECHNICAL EXPERIENCE
Aug. 2007 to ARUP Laboratories, Salt Lake City, UT
July 2010
Technologist II, ASCP (C)
Performed and analyzed laboratory testing in biochemical genetics—e.g., cell cultures, enzymatic
reactions, electrophoresis, ion exchange chromatography, mass spectrometry, and spectrophotometer and
solid-phase extraction.

June 2006 to University of Utah—Keck Center for Tissue Engineering, Salt Lake City, UT
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Apr. 2007

Research Assistant

Studied the expression of cytokines in astrocytes cells under 2-D vibration. Presented research in a poster
session and presented in the senior project symposium.

June to Aug. Pacific Northwest National Laboratory, Richland, WA
2004 CCI Fellowship
Investigated “ridge-” like structures using Rutherford backscattering spectrometry, scanning electron
microscopy, energy dispersive x-ray emission, atomic force microscopy, and high-resolution transmission
electron microscopy. Abstract of my research was published in the U.S. Dept. of Energy Journal of
Undergraduate Research.

LEGAL PUBLICATION
Chico Gholz, Lisa Mandrusiak & Jeremy Barton, Spoliation in Interferences, IPToday Oct. 2012
VOLUNTEER WORK
Assistant Scoutmaster (Apr. 2008 to July 2010)
Missionary for the LDS Church in Santa Maria, Brazil (2000 to 2002)
LANGUAGES
Fluent in Portuguese
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JEFF JANOVETZ
34A Lyndon St.
Concord, NH 03301
Tel: 616-450-0628
Email: jeffrey.janovetz@law.unh.edu

EDUCATION
J.D. 2013 (expected). Franklin Pierce Law Center (currently The University of New
Hampshire School of Law), Concord, NH
Ph.D. 2002. Division of Biological Sciences, University of Chicago, Chicago, IL
M.S.

1996. School of Biological Sciences, Washington State University, Pullman, WA

B.S.

1992. Department of Biology, University of Illinois, Champaign, IL, cum laude

LEGAL WORK EXPERIENCE
Toohey Law Group, LLC., Manchester, NH
Student Associate working exclusively for DEKA Research and Development, 2012 - current.
International Technology Transfer Clinic, Concord, NH
Project: Developing a patent landscape for pandemic influenza vaccines to assist the World
Health Organization in the event of an outbreak.
Oliff and Berridge, PLC., Alexandria, VA
Intellectual property externship, spring semester 2013.
ACADEMIC WORK EXPERIENCE
Grand Valley State University, Allendale, MI
Assistant Professor, Biomedical Sciences Department, 2009 – 2010.
Centre College, Danville, KY
Assistant Professor, Department of Biology, 2006 – 2009.
Sweet Briar College, Sweet Briar, VA
Assistant Professor, Department of Biology, 2002 – 2006.
Each position involved designing and teaching courses as the sole instructor. Subjects taught
include human anatomy and physiology, comparative anatomy, comparative physiology,
genetics, general biology, and scanning electron microscopy. I established a research lab,
conducted research as the principal investigator, and supervised student research. I wrote and
received external grants, and published primary research in peer-reviewed journals. I directed the
Scanning Electron Microscopy Center and administered the Center’s budget.
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SELECTED PUBLICATIONS and MEETING PRESENTATIONS
2005 Janovetz, J. Functional Morphology of Feeding in the Scale-eating Specialist, Catoprion
mento. Journal of Experimental Biology 208: 4757 – 4768.
2005 Janovetz, J. Society of Integrative and Comparative Biology, San Diego, CA. Functional
Morphology of Prey Capture in Serrasalmine Fishes. American Zoologist 44:30.10A.
2005 Lambert*, B., and J. Janovetz. Mid-Atlantic Regional Conference of Undergraduate
Scholarship, Sweet Briar, VA. Feeding Kinematics and Jaw Protrusion in the Creek Chub,
Semotilus atromaculatus.
2005 Janovetz, J. American Society of Ichthyologists and Herpetologists, Tampa, FL.
The Kinematics of Biting Prey Capture in Pacus, Silver Dollars, and Piranhas.
2004 Janovetz, J. Society of Integrative and Comparative Biology, New Orleans, LA.
Functional Morphology of Feeding in the Scale-eating Piranha, Catoprion mento. American
Zoologist, 43:30.8A.
2003 McGuffey*, S., and J. Janovetz. Mid-Atlantic Regional Conference of Undergraduate
Scholarship, Sweet Briar, VA. The Effects of Pavlovian Conditioning on the Anti-predator
Behavior of Hognose Snakes.
2002 Janovetz, J. Society of Integrative and Comparative Biology, Anaheim, CA.
Biomechanics of Feeding in a Scale-eating Piranha: A Novel Feeding Behavior Using Extreme
Jaw Rotation and Momentum Transfer. American Zoologist 41:10.1A.
2002 Janovetz, J. Functional and Ecological Morphology of Feeding in Pacus, Silver Dollars,
and Piranhas (Serrasalminae: Teleostei). Ph.D. thesis, University of Chicago.
2001 Alfaro, M.E., J. Janovetz, and M.W. Westneat. Motor Control across Trophic Strategies:
Muscle Activity of Biting and Suction Feeding Fishes. American Zoologist 41(6):1266-1279.
1999 Janovetz, J. Society of Integrative and Comparative Biology, Regional Meeting, Athens,
OH. Evolution of Feeding Behavior in Serrasalmine Fishes. Best Student Paper award.
* denotes undergraduate co-author
PROFESSIONAL ACTIVITIES
Include reviewing and editing manuscripts for The Biological Journal of the Linnaean Society,
Animal Behavior, Philosophical Transactions Royal Society London B, Behavioral Ecology and
Sociobiology, Copeia, Oecologica, Functional Ecology.
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John Schroeder
(918) 688-2094

104 Pleasant St. Concord, NH 03302
John.Schroeder@law.unh.edu

Education
University of New Hampshire School of Law, Concord, NH
Juris Doctor Candidate, May 2014
Activities:
International Technology Transfer Clinic
Current member of Student Intellectual Property Law Association
Current parliamentarian of the Black Law Student Association
Hendrix College, Conway, AR
Bachelor of Arts in History and Biology, January 2011
Activities:
Teaching Assistant for Zoology Laboratory, fall term of 2009
Teaching Assistant for Botany Laboratory, spring terms of 2009 and 2010
Laboratory Assistant for Cell Biology, fall term of 2008
Experience
New Hampshire District Court Circuit Court Division –Internship June 2012 – Present
 Assisted in updating the New Hampshire judicial bench book, a manual containing the
current New Hampshire jurisprudence designed to assist new judges in all areas of law.
Hendrix College - Assistant Laboratory Technician for Dr. Jennifer Dearolf May 2010 - December
2010
 Analyzed the percentage of different myosin isoforms present in the scalenus muscle of fetal
guinea pigs.
 Responsible for gathering and interpreting data collected by eight former lab assistants
necessary for publication of professor’s findings.
Hendrix College- Summer Laboratory intern for Dr. Jennifer Dearolf, May 2009- May 2010
 Characterized the myosin profile of the rectus thoracis muscle collected from fetal guinea
pigs.
Community Service
 Co-President of The Hendrix College chapter of Habitat for Humanity, 05/10 - 12/10
Presentations and Publications
 Co-author of presentation, Effects of prenatal steroids on myosin heavy chain expression of
breathing and locomotor muscles. SE Regional IDeA Meeting - September 22-24, 2011,
New Orleans, LA
 Oral Presentation of The effects of glucocorticoids on myosin expression patterns of fetal
Cavia porcellus hindlimb and ventilatory musculature at the Society for Integrated and
Comparative Biology 2011 Annual Meeting - January 3-7, 2011, Salt Lake City, Utah
 Poster Presentation of The effects of betamethasone on myosin expression patterns of fetal
Cavia porcellus rectus thoracis and scalenus muscles at Third Biennial National IDeA
Symposium - June 16-18, 2010, Washington DC, 2010
 Poster Presentation of The effects of betamethasone on myosin expression patterns of fetal
Cavia porcellus rectus thoracis muscle at the Society for Integrated and Comparative
Biology 2010 Annual Meeting - January 3-7, 2011, Seattle, WA, 2010
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